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Abstract 
It is imperative that smoking cessation aids effectively alleviate cigarette craving 
and withdrawal symptoms because their intensity has shown to predict relapse. 
The nicotine lozenge is a pharmacotherapy that has shown to reduce symptoms 
of craving and withdrawal. Research has also shown that a single session of 
exercise can provide temporary relief from craving and withdrawal for smokers 
who are both temporarily abstaining and undergoing a real quit attempt. Applying 
two efficacious monotherapies concurrently may provide additive benefit and 
greater symptom relief. Thirty recently quit smokers were randomized to either 
the experimental (exercise and lozenge) or control (lozenge alone) condition. 
While both conditions demonstrated reductions in craving, the reduction was 
significantly greater for the experimental group. These findings demonstrate that 
an acute bout of exercise provides additional craving relief to the nicotine lozenge 
in recently quit smokers.  
 
 Keywords: smoking, nicotine lozenge, acute exercise, craving, withdrawal 
 symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   iii 
Acknowledgements 
This research project would not have been possible without the support of many 
people. To my supervisor Harry Prapavessis. Thank you for the guidance you 
have provided me over the past 5 years. Apart from the science, you have taught 
me valuable life lessons that I will cherish forever. To my teammate Lyndsay. I 
could not ask for a more spectacular mentor, colleague, and friend. Thank you for 
instilling the confidence in me that you have and setting the bar high for me in life. 
I have had the opportunity to become colleagues and friends with several 
researchers in the EHPL during my time. To those who have come and gone and 
those that remain, thank for you for making this experience as positive as it has 
been. My friends and family–those near and far–you have provided me with 
stability when I needed grounding, motivation when I needed a push, and 
laughter when I needed to smile. Thank you for embarking with me on my 
scholarly adventure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   iv 
Table of Contents 
Abstract……………………………………………………………………..…………….ii 
Acknowledgments………………………………………………………...…………….iii 
List of Tables…………………………………………………………………..………..vi 
List of Figures……………………………………………………………………...…...vii 
List of Appendices……………………………………………………………………..viii 
Chapter One: Literature Review……………………………………………………….1 
     Introduction………………………………………………………………………..........1 
     Nicotine Dependence…….………………………………………………….………...2 
     Nicotine Replacement Therapy (NRT)……………………………………………….8 
     Acute Effects of Exercise.……………………………………………………………12 
     Possible Mechanisms of Acute Exercise Effects……………………………….…17 
     Combining Acute Exercise with a Nicotine Lozenge……………………………..22 
     Purpose and Hypothesis………………………………………………………….....24 
Chapter Two: The Current Study…………………………………………………….25 
     Methods……………………..…………………………………………………………25 
     Design...……………………..………………………………………………………...25 
     Participants……………………..……………………………………………………..25 
     Primary Outcome Measure…………………………………………...............…….26 
     Secondary Outcome Measure…………...…………………………….……...........26 
     Other Measures……………………..………………………………….………….....27 
     Intervention……………………..……………………………………....………...…..28 
     Procedure……………………..………………………………………...………….....29 
     Sample Size Calculation……...…………………………………………………......34 
 
	   v 
     Statistical Analyses……………………..……………………………………….......34 
     Results……………………..………………………………………………………….36 
     Treatment of Data……………………..…………………………………………......36 
     Fidelity Check……………………..……………………………………………….....39 
     Group Equivalency at Baseline……………………..………………………...........39 
     Main Analyses……………………..………………………………………...............42 
Chapter Three: Discussion……………………………………………………………52 
     Craving……………………..…………………………………………………….……52 
     Withdrawal Symptoms……………………..…………………………….…………..56 
     Strengths and Limitations……………………………………………………….…...60 
     Conclusions……………………..…………………………………………………….61 
References…………………...…………………………………………………………62 
Appendix A……………………...………………………………………………………83 
Appendix B…..………………………………………………………………………....94 
Curriculum Vitae for Amelia Tritter….……..……………………………………….105 
 
 
 
 
 
 
 
 
 
 
 
 
	   vi 
List of Tables 
Table 1: Abstinence at Six Months for Smoking Cessation Strategies………..…..8 
Table 2: Schedule of Measures………………………………………………………32 
Table 3: Demographic and Smoking Behaviour Variables………………………..41 
Table 4: Means, Standard Deviations, and 95% Confidence Intervals for  
Craving Before, During, and After Treatment…..…………………………….…….43 
Table 5: Means, Standard Deviations, and 95% Confidence Intervals for 
Restlessness Before, During, and After Treatment………………………………..45 
Table 6: Means, Standard Deviations, and 95% Confidence Intervals for  
Irritability Before, During, and After Treatment…………………………….……….47 
Table 7: Means, Standard Deviations, and 95% Confidence Intervals for Poor 
Concentration Before, During, and After Treatment…………..…………………...49 
Table 8: Correlations Between Residuals for Craving and Withdrawal 
Symptoms…..…………………………………………………………………………..51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   vii 
List of Figures 
Figure 1: Pilot sample’s craving relative to time.....………………………………...33 
Figure 2: Flow of participants through the study……………………………………38 
Figure 3: Craving relative to time. ………………………………..………………….44 
Figure 4: Restlessness relative to time…………………………………..………….46 
Figure 5: Irritability relative to time……………………………………...……………48 
Figure 6: Poor concentration relative to time…………………………….…………50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   viii 
List of Appendices 
Appendix A……………………………………...……………………………………..83 
     Recruitment Poster……………………..…………………………….………………84 
     Recruitment E-mail……………………..…………………………….………………85 
     Ethics Approval……………………..…………………………….…………………..86 
     Letter of Information……………………..…………………………….……………..87 
Appendix B……………………………………...……………………………………..94   
     Craving……………………….…………………..…………………………….……...95 
     Withdrawal Symptoms………………………………………………………………..96 
     Demographic and Smoking Behaviour Questionnaire…………………………....97 
     International Physical Activity Questionnaire (Short-form)..………….................98 
     Fagerström Test for Cigarette Dependence………………………………………103 
     Physical Activity Readiness Questionnaire………………………………………..104 
1 
Chapter One: Literature Review 
 
Introduction 
 Cigarette smoking continues to be the leading cause of preventable death 
in the world today (World Health Organization [WHO], 2011), accounting for more 
than 37,000 deaths each year in Canada alone (Baliunas et al., 2007). The 
negative health consequences of smoking have been thoroughly researched. 
While lung cancer has long been identified as the disease of smokers, the 
detriments of smoking are much more broad. Several other cancers have been 
linked to smoking as well, including: mouth, larynx, throat, esophagus, bladder, 
kidney, cervix, pancreas, and stomach. Furthermore, smoking has shown to lead 
to cardiovascular diseases such as stroke and coronary heart disease. In 
general, smoking harms nearly every organ in the body and affects a person’s 
overall health (U.S. Department of Health and Human Services [USDHHS], 
2014). 
 Despite the unfavourable morbidity and mortality outcomes associated 
with smoking, a significant proportion of the population continues to engage in 
this behaviour. It is estimated that approximately 16% of Canadians aged 15 
years or older smoke (Health Canada, 2012). Fortunately for these individuals, it 
is never too late to reap the benefits of quitting. The risks associated with many of 
the aforementioned diseases can be reduced or largely removed by stopping 
smoking. These benefits commence almost immediately, with a decrease in heart 
rate occurring within 20 minutes of abstinence. Other short-term benefits of 
quitting include: removal of carbon monoxide (CO) from the blood and improved 
2 
lung function and blood circulation. The long-term benefits are even more 
motivating. For example, the risk of coronary heart disease is cut in half after 1 
year of quitting and can drop to the level of a non-smoker after 15 years. In 
addition, the risk of stroke can be reduced to that of a non-smoker within 5 to 15 
years of quitting. After 10 years of being smoke-free, the risk of several cancers 
(i.e., mouth, throat, esophagus, bladder, and cervix) decrease and one’s lung 
cancer death rate becomes approximately half that of a smoker’s (USDHHS, 
2004). Although stopping smoking at a younger age reduces health risks to a 
greater degree, quitting at any age is beneficial and can give back years of life 
that would be lost by continuing to smoke. 
 Given these health benefits, it may come to no surprise that the majority of 
smokers want to quit. Unfortunately, only 3 to 5% of those who quit unassisted 
remain smoke-free after 6 to 12 months (Hughes, Keely, & Naud, 2004) and 
nearly half of those who undergo surgery for early-stage lung cancer return to 
smoking (Walker et al., 2006). These findings are not only discouraging but also 
indicative of the degree of difficulty that presents itself when trying to quit. So, 
what makes quitting smoking so challenging? The answer to this question is 
multifaceted and requires an understanding of the factors that contribute to 
nicotine dependence. 
 
Nicotine Dependence 
 As reported by the Royal College of Physicians of London (2000), nicotine 
is a highly addictive drug on par with heroin and cocaine. Nicotine is recognized 
as a substance that meets the criteria for dependence defined in the International 
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Classification of Diseases, tenth edition (ICD-10; WHO, 1992). These symptoms 
include: tolerance, withdrawal, impaired control, neglect of activities, time spent in 
substance-related activity, continued use despite problems, and compulsion. The 
criteria described in the ICD-10 are similar to those found in the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition (DSM-IV; American 
Psychiatric Association, 2000); with the exception that the DSM-IV does not 
explicitly state the compulsion criteria (i.e., strong desire or sense of compulsion 
to use). Both systems require at least three co-occurring criteria within a 12-
month period to diagnose dependence (Hasin, Hatzenbuehler, Keyes, & Ogburn, 
2006). 
 Nicotine is the major psychoactive constituent in tobacco (Karan, Dani, & 
Benowitz, 2003) and can be found in various tobacco products. The cigarette is 
the most efficient device, delivering nicotine to the brain within 7 seconds of 
inhalation (Maisto, Galizio, & Connors, 2004). The average smoker absorbs 1 to 
2 mg of nicotine per cigarette (Karan et al., 2003) and metabolizes the drug 
relatively quickly, with nicotine blood concentration levels dropping by half within 
2 to 3 hours of smoking (Lynch & Bonnie, 1994). The neurological effect of 
nicotine serves as a powerful driving force of this disorder; however, behavioural, 
genetic, and socio-environmental factors contribute as well.  
 Neurological factors. Nicotine activates the mesolimbic pathway, known 
as the “reward centre” of the brain that controls feelings of pleasure and 
motivation (Gardner, 1997). The mesolimbic pathway originates in the midbrain 
and is composed of the ventral tegmental area (VTA) and nucleus accumbens 
(NAc). The VTA houses dopaminergic projections that extend to the NAc, limbic 
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brain regions, and the prefrontal cortex. Embedded on the plasma membrane of 
dopaminergic neurons are nicotinic acetylcholine receptors (nAChRs) that are 
activated by the neurotransmitter acetylcholine (ACh; Gardner, 1997). These 
receptors can also be stimulated by nicotine (Calabresi, Lacey, & North, 1989), 
which has particularly high-affinity to α4β2 subunits (Lukas et al., 1999). When 
nicotine or ACh bind to nAChRs, the ion-gated channels open and a subsequent 
action potential is fired down the dopaminergic axons to the terminal found in the 
NAc. The neurotransmitter dopamine is then released from the synaptic vesicles 
and into the cleft. Dopamine elicits euphoric feelings and reinforces future 
engagement in smoking behaviour (Benowitz, 2010; Wonnacott, Sidhpura, & 
Balfour, 2005). The binding of nicotine stimulates the release of other 
neurotransmitters as well, which produce a range of psychoactive effects. These 
neurotransmitters and their associated responses include: ACh (arousal and 
cognitive enhancement), norepinephrine (arousal and appetite suppression), 
glutamate (learning and memory enhancement), serotonin (mood modulation and 
appetite suppression), β-endorphin (reduction in anxiety and tension), and GABA 
(reduction in anxiety and tension; Benowitz, 2008).  
 Prolonged nicotine exposure causes neuroadaptations (Wang & Sun, 
2005) and leads to drug tolerance, where a higher nicotine dose is required to 
produce the same magnitude of effect (Smith & Stolerman, 2009). The exact 
adaptations the brain undergoes in response to nicotine have been debated, 
however, desensitization and upregulation seem most probable (Ortells & 
Barrantes, 2010). The desensitization-upregulation hypothesis is as follows: 1) 
Excess and chronic nicotine exposure saturates α4β2 nAChRs and induces an 
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activated state. 2) The nAChRs become desensitized as binding-sites are 
occupied with high-affinity. 3) The homeostatic response to desensitization is 
upregulation, whereby a greater number of nAChRs are produced (Ortells & 
Barrantes, 2010). It has been suggested that during periods of nicotine 
abstinence, previously desensitized nAChRs become unoccupied and recover to 
a responsive state. Together, the increase in number of nAChRs and reactivation 
of desensitized receptors are thought to be responsible for cigarette cravings and 
the array of withdrawal symptoms (e.g., irritability, depressed mood, restlessness, 
anxiety, difficulty concentrating, increased hunger and eating, and insomnia) that 
emerge in nicotine-deprived smokers (Dani & Heinemann, 1996).  
 Behavioural factors. With habitual smoking, smokers become familiar 
with the pleasant state elicited by cigarettes and the unfavourable symptoms that 
accompany short-term abstinence. Becoming aware of, and ultimately learning, 
these consequences of smoking (or not smoking) impacts future behaviour. This 
method of learning is known as operant conditioning, where an individual’s 
behaviour is influenced by its outcomes. These consequences (or 
reinforcements) can be positive or negative, and in turn, strengthen or weaken 
the behaviour accordingly (Skinner, 1938). For example, the psychoactive effects 
of nicotine serve as a reward, and thus, positively reinforce smoking (Glautier, 
2004). Conversely, craving and withdrawal symptoms serve as a punishment, 
and as a result, negatively reinforce quitting (Eissenberg, 2004). Together, these 
behavioural consequences strengthen future smoking behaviour and reduce the 
likelihood quitting.   
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 The average Canadian smoker consumes 15 cigarettes per day (Health 
Canada, 2012) and takes approximately 11 puffs per cigarette (USDHHS, 1988). 
This exposes smokers to more than 150 doses of nicotine daily. As a result, 
smokers are likely to develop associations with this drug because it is 
administered at such a high frequency. The repetitive nature of smoking and the 
associations that develop with this behaviour can be explained by Pavlov’s 
(1927) classical conditioning theory. Classical conditioning occurs when an 
initially neutral stimulus produces the same response as an existing stimulus with 
which it has been paired. This process entails three stages (i.e., before, during, 
and after conditioning). Before conditioning, smoking serves as the unconditioned 
stimulus (UCS) and cigarette cravings and withdrawal symptoms serve as the 
unconditioned response (UCR). During the conditioning stage, a neutral stimulus 
becomes associated with the UCS. In regards to smoking, environmental stimuli 
that occur repeatedly in temporal proximity become conditioned stimuli (CS) and 
can include smoking paraphernalia (e.g., an ashtray), sensory aspects of 
smoking (e.g., cigarette smell or taste), and/or situational cues (e.g., smoking 
while drinking coffee). After conditioning, the mere presence of CSs alone can 
trigger craving and withdrawal symptoms, which now become a conditioned 
response (CR; Bevins & Palmatier, 2004; Niaura, 2000). Classical and operant 
conditioning are two behavioural theories that help explain the learned 
component of this disorder. 
 Genetic factors. Certain smokers may be at greater risk of becoming 
addicted to nicotine due to genetic predispositions. Nicotine is primarily 
metabolized into cotinine, and cotinine is metabolized into 3-hydroxycotinine by 
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the liver enzyme cytochrome CYP2A6. Research reveals that polymorphic 
variations of the CYP2A6 gene influence the rate at which nicotine is metabolized 
(high vs. low activity), which in turn, impact nicotine dependence, smoking 
behaviour, and withdrawal symptoms. For example, smokers with a high-activity 
variation of the gene have a tendency to smoke a greater number of cigarettes 
per day, intake more nicotine daily, and smoke their first cigarette earlier in the 
day compared to those with a low-activity variant. This heavy smoking behaviour 
translates into a higher nicotine (or cigarette) dependence score. In addition, 
among those attempting to quit, high-activity carriers report greater withdrawal 
symptoms than their low-activity counterparts (Kubota et al., 2006). 
 Socio-environmental factors. Many social and environmental factors 
contribute to the development and maintenance of nicotine dependence as well 
as the likelihood of relapse (WHO, 2010). Environmental influences, such as 
being in the presence of smokers (i.e., peers, family, or strangers), can 
encourage smoking behaviour. Furthermore, marketing, portrayal in the media, 
and brand preference of specific populations can influence the progression 
towards habitual smoking (Royal College of Physicians, 2007). However, 
environmental factors can also discourage tobacco use. Developing and 
enforcing smoke-free policies as well as increasing taxes can serve as barriers to 
smoking, and thus, reduce initiation rates and promote cessation attempts (WHO, 
2010). 
 The interplay of these factors influences the development and resiliency of 
this disorder, as well as the challenges associated with quitting. A significant 
portion of tobacco control efforts has been directed towards developing 
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individual-based cessation interventions that facilitate quitting and remaining 
smoke-free. Of the various modalities and settings offered, behavioural 
counseling and pharmacotherapy, used alone or in combination, have shown to 
yield the greatest success (USDHHS, 2008). The effectiveness of some 
cessation strategies can be found in Table 1. 
 
Table 1 
Abstinence at Six Months for Smoking Cessation Strategies (USDHHS, 2008) 
Cessation strategies            % abstinent [95% CI] 
Physician advice to quit  10.2 [8.5, 12.0] 
Behavioural interventions   
    Proactive telephone counseling  13.1 [11.4, 14.8] 
    Group counseling  13.9 [11.6, 16.1] 
    Individual counseling  16.8 [14.7, 19.1] 
Pharmacotherapy interventions   
    Nicotine patch (6 – 14 weeks)  23.4 [21.3, 25.8] 
    Nicotine gum (6 – 14 weeks)  19.0 [16.5, 21.9] 
    Nicotine lozenge (2 mg)   24.2a 
    Nicotine inhaler  24.8 [19.1, 31.6] 
    Bupropion SR  24.2 [22.2, 26.4] 
    Varenicline (2 mg/day)  33.2 [28.9, 37.8] 
Note. CI = Confidence Interval 
aOne qualifying randomized trial; 95% CI not reported 
 
Nicotine Replacement Therapy (NRT) 
 Currently Health Canada's Therapeutic Products Directorate has approved 
six smoking cessation medications, including four NRT formulations (patch, gum, 
lozenge, and inhaler) and two non-NRT compounds (bupropion and varenicline 
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tartrate). It is imperative that cessation aids effectively manage craving and 
withdrawal symptoms because their intensity has shown to predict relapse 
(Swan, Ward, & Jack, 1996). NRT has been recognized as a first line treatment 
for smoking cessation, in part because it suppresses these symptoms. The 
fundamental mechanism by which all NRT formulations exert their effect is by 
binding to nAChRs that were formerly activated by nicotine obtained from 
cigarettes (Shiffman, Fant, Buchhalter, Gitchell, & Henningfield, 2005). The 
transdermal patch is an easy, convenient formulation that releases nicotine into 
the skin at a steady state (Shiffman et al., 2005). Research has shown that the 
patch effectively alleviates background cravings (Rose, Herskovic, Trilling, & 
Jarvik, 1985), which are constantly present and require no triggering stimuli 
(Shiffman, 2000). However, this passive modality does not protect users against 
episodic craving (Tiffany, Cox, & Elash, 2000; Waters et al., 2004). Episodic 
cravings are acute, intense, and typically provoked by environmental (e.g., 
someone smokers) or affective (e.g., emotional distress) stimuli (Shiffman, 2000). 
These acute craving episodes are particularly problematic because they are 
associated with a very high risk of relapse (Shiffman, Paty, Gnys, Kassel, 
Hickcox, 1996). Therefore, being able to quickly administer a dose of nicotine 
during an “at-risk” moment will help avoid a lapse (Shiffman et al., 2005). 
 Oral NRT. Several fast-acting oral NRT formulations are available in 
Canada, including the nicotine gum, lozenge, and inhaler. These products deliver 
nicotine through the oral mucosa membrane that lines the inside of the mouth. 
Orals NRTs offer the following advantages compared to the patch. Firstly, 
maximum nicotine blood concentrations are reached faster (in less than 1 hour; 
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McRobbie et al., 2010). Secondly, the user can control the amount and timing of 
dosing on an “as needs basis” (Shiffman et al., 2005). Lastly, the oral 
administration of these formulations mimics some of the sensory cues associated 
with the smoking behaviour (i.e., oral stimulation; Muramoto, Ranger-Moore, & 
Leischow, 2003).  
 A recent Cochrane review by Stead and colleagues (2012) revealed that 
the nicotine gum, lozenge/tablets, and inhaler are all effective smoking cessation 
aids, with respective pooled risk ratios of 1.49 (95% CI [1.40, 1.60], 55 trials), 
1.95 ([1.61, 2.36], 6 trials), and 1.90 ([1.36, 2.67], 4 trials) compared to placebo or 
non-NRT control groups. While they exhibit comparable efficacy profiles, other 
factors must be weighed when selecting the most appropriate product for a 
single-dose randomized controlled trial. Two important factors to consider are: 1) 
standardization of the amount of nicotine consumed and 2) ease of drug 
administration. The lozenge allows for more consistent nicotine dosing, whereas, 
several confounding variables may influence amount of nicotine absorbed by the 
gum and inhaler modalities. For example, up to 50% of the nicotine can remain in 
the gum if not properly chewed (Benowitz, Jacob, & Savanapridi, 1987). In 
addition, the number and depth of inhalations as well as environmental factors, 
such as room temperature, impact the amount of nicotine absorbed from the 
inhaler (Lunell, Molander, & Andersson, 1997). The lozenge is also easier to 
administer and demands less activity (i.e., passively dissolves in mouth) than the 
gum (i.e., chew-and-park technique) or the inhaler (i.e., requires continuous 
puffing).   
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 Nicotine lozenge. A single nicotine lozenge has shown to significantly 
reduce cigarette craving and withdrawal symptoms in temporarily abstaining 
smokers. In a double-blinded, placebo-controlled, randomized-controlled 
crossover trial, McRobbie and colleagues (2010) examined the effect of a 2.5 mg 
nicotine lozenge in the initial 60 minutes of product use. Cigarette craving and 
withdrawal symptoms were assessed on 100 mm visual analogue scales. The 
lozenge group reported a mean change craving score of -24.7 (SE = 2.8), which 
was significantly greater than that of the placebo group, Mdiff = -15.8, 95% CI [-
23.7, -7.9], p < .0001. Significant group differences in craving were found within 
10 minutes of product placement. In regards to withdrawal symptoms, the 
lozenge group reported mean reductions for irritability, restlessness, and poor 
concentration of 9.6 (SE = 2.2), 10.8 (SE = 2.0), and 7.1 (SE = 2.0), respectively. 
The lozenge group had significantly greater decreases than the placebo for 
irritability, Mdiff = -7.6, [-14.6, -.7], p = .02, restlessness, Mdiff = -10.0, [-16.5, -3.5], 
p = .0006), and poor concentration, Mdiff = -7.5, [-14.2, -.7], p = .02. 
 Shahab, McEwen, and West (2011) examined the effects of a 4 mg 
nicotine lozenge on cigarette craving and withdrawal symptoms in a single-
blinded, randomized-controlled crossover trial. Significant decreases in craving 
(i.e., urge to smoke and desire for cigarette) were reported over the 20-minute 
assessment period. Of the five withdrawal symptoms assessed (i.e., depressed 
mood, irritability, restlessness, hunger, and poor concentration), significant 
reductions were found for poor concentration and restlessness from before to 
after NRT use. Similarly, Kotlyar and colleagues (2007) found that a 4 mg 
lozenge resulted in significant linear decreases in cigarette craving and 
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aggregated withdrawal symptoms from before to 5, 10, and 30 minutes after 
product placement.  
 These findings corroborate the efficacy of the nicotine lozenge and its 
ability to reduce craving and withdrawal symptoms. However, as advised by 
pharmaceutical companies, NRTs should be augmented with other treatments to 
maximize symptom relief. Applying two efficacious monotherapies concurrently 
may provide additive benefit and greater symptom relief.  Meditation, deep 
breathing, cognitive relaxation techniques, and exercise are examples of acute 
strategies that have been postulated to relieve cravings and could be 
implemented with a nicotine lozenge. Of these adjunctive strategies, exercise is 
the strongest contender because its effects on craving and withdrawal symptoms 
have been most scientifically validated. 
 
Acute Effects of Exercise 
 The effects of acute exercise on nicotine-deprived smokers have been 
comprehensively studied and summarized in several systematic reviews (i.e., 
Hassova et al., 2013; Roberts, Maddison, Simpson, Bullen, & Prapavessis, 2012; 
Taylor, Ussher, & Faulkner, 2007). 
 Cigarette craving. Two meta-analyses (i.e., Hassova et al., 2013; Roberts 
et al., 2012) have quantified the effect of exercise on cigarette cravings. Roberts 
and colleagues used aggregate data to conduct their analyses, whereas Hassova 
et al. used individual participant data (IPD), which is a more rigorous statistical 
approach. The included studies used a temporary abstinence paradigm and 
involved different types (e.g., isometric, aerobic) and modes (e.g., cycling, 
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walking, running, and isometric) of exercise that ranged in intensity (light to 
vigorous) and duration (5 to 18 minutes). Craving was assessed using the ‘desire 
to smoke’ (DtS) and/or ‘strength of desire to smoke’ (SoD) item(s), both of which 
are rated on 7-point Likert scales. 
 The meta-analyses (Hassova et al., 2013; Roberts et al., 2012) concluded 
that a single bout of exercise has a positive effect on cigarette craving. Based on 
the aggregated data of 10 trials (Arbour-Nicitopoulos, Faulkner, Hsin, & Selby, 
2011; Faulkner, Arbour-Nicitopoulos & Hsin, 2010; Janse Van Rensburg & 
Taylor, 2008; Janse Van Rensburg, Taylor, Bennattayallah, & Hodgson, 2012; 
Janse Van Rensburg, Taylor, & Hodgson, 2009a; Janse Van Rensburg, Taylor, 
Hodgson, & Benattayallah, 2009b; Scerbo, Faulkner, Taylor, & Thomas, 2010; 
Taylor & Katomeri, 2007; Taylor, Katomeri, & Ussher, 2006; Ussher, Nunziata, 
Cropley, & West, 2001), Roberts and colleagues (2012) calculated a weighted 
mean difference in DtS between exercise and control conditions of -1.90 points, 
95% CI [-3.06, -.075], in favour of exercise. Similarly, the weighted mean 
difference in SoD of nine trials (Everson, Daley, & Ussher, 2006, 2008; Janse 
Van Rensburg et al., 2012; Scerbo et al., 2010; Taylor & Katomeri, 2007; Taylor, 
Katomeri, & Ussher, 2005; Ussher, Cropley, Playle, & Mohidin, 2009; Ussher et 
al., 2001; Ussher, West, Doshi, & Sampuran, 2006) favoured the exercise 
condition by -2.41 points, [-3.45, -1.37]. These findings are analogous to those 
reported by Hassova and colleagues who used individual participant data. For 
example, across 17 studies (Daniel, Cropley, & Fife-Schaw, 2006; Daniel, 
Cropley, Ussher, & West, 2004; Faulkner et al., 2010; Haasova, Oh, & Taylor, 
2011; Janse Van Rensburg, Elibero, Drobes, Ehlke, & Watson, 2011; Janse Van 
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Rensburg & Taylor, 2008; Janse Van Rensburg et al., 2012, 2009a, 2009b; 
Katomeri, 2009; Oh, 2011; Scerbo et al., 2010; Taylor & Katomeri, 2007; Taylor 
et al., 2005; Thompson, 2009; Ussher et al., 2001, 2006), the weighted mean 
difference on DtS between exercise and control conditions was -2.04 points, 95% 
CI [-2.60, -1.46], in favour of exercise. Furthermore, their meta-analysis of 15 
studies (Daniel et al., 2006, 2004; Everson et al., 2008; Faulkner et al., 2010; 
Haasova et al., 2011; Janse Van Rensburg et al., 2012; Katomeri, 2009; Oh, 
2011; Scerbo et al., 2010; Taylor & Katomeri, 2007; Taylor et al., 2005; 
Thompson, 2009; Ussher et al., 2009, 2001, 2006) favoured the exercise 
condition by -1.91 points, [-2.59, -1.22] for SoD. The effect sizes found in these 
studies were moderate to large in size (ranging from d = 0.4 to 1.9; Cohen, 1988). 
This is comparable to, or many cases exceed the effect sizes found with oral 
NRTs.  
 With respect to craving time effects, the magnitude of craving relief 
appears greatest during, or immediately after exercise. However, significant 
effects have been shown to last up to 30 minutes post-exercise (Scerbo et al., 
2010; Ussher et al., 2009). The speed at which exercise relieves urges to smoke 
may be faster than that of the nicotine lozenge. While significant reductions have 
been reported within 3 to 5 minutes of administering a lozenge, maximal relief is 
not attained until after 30 minutes (Hansson, Hajek, Perfekt, & Kraiczi, 2012). The 
timing of this effect is in accordance with pharmacokinetic studies that reveal 
maximal blood nicotine levels at 25 (McEwen, West, & Gaiger, 2008) and 30 
minutes (Kotlyar et al., 2007) post-administration. 
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 Exercise-induced reductions in cigarette craving have been observed with 
various types of exercise and across all intensities. Even 10 minutes of isometric 
exercise (Ussher et al., 2009) or a low-intensity yoga session (Elibero, Janse Van 
Rensburg, & Drobes, 2011) have shown to significantly reduce craving relative to 
passive controls. However, recent work by Hassova and colleagues (2014) found 
that the benefits of exercise are significantly influenced by the intensity at which it 
is performed. Hassova et al. (2014) conducted a one-stage IPD meta-analysis on 
930 subjects. They rescaled the DtS and SoD craving items from 0 to 100, thus a 
difference between groups of -10 indicated that post-intervention craving scores 
were 10% lower in the exercise group compared to the controls. The analysis 
revealed mean differences of -9.22, 95% CI [-15.24, -3.20], -34.56 [-2.59, -1.22], 
and -31.29 [-2.59, -1.22], for light-, moderate-, and vigorous-intensity exercise, 
respectively. Thus, as previously shown by Hassova et al. (2013), exercising at a 
light intensity results in craving reductions of a smaller magnitude compared to 
those resulting from moderate or vigorous intensities. However, no significant 
difference exists between the effects of moderate- and vigorous-intensity 
exercise on craving relief. In other words, there seems to be no additional benefit 
from engaging in vigorous as opposed to moderate-intensity exercise (Hassova 
et al., 2014). This finding is advantageous from a clinical standpoint because 
moderate-intensity exercise (e.g., brisk walking) is more convenient and tolerable 
than vigorous-intensity exercise. Therefore, quitters may be more likely to 
execute and adhere to this behaviour.  
 Withdrawal symptoms. Exercise has shown to reduce various withdrawal 
symptoms, including irritability, depression, tension, restlessness, difficulty 
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concentrating, and stress (Roberts et al., 2012). However, the effects of exercise 
on withdrawal symptoms are inconsistent compared to craving. As a result, less 
research has been devoted to examining withdrawal symptoms and no meta-
analysis has been conducted on this outcome to date. The findings described 
below are based on the systematic review provided by Roberts and colleagues 
(2012). Three of the five studies (Arbour-Nicitopoulos et al., 2011; Daniel, 
Cropley, & Fife-Schaw, 2007; Everson et al., 2008; Ho, 2009; Ussher et al., 2009) 
that used the Mood and Physical Symptoms Scale (MPSS) and variations of the 
scale (i.e., included stress and tension items) found significant reductions in at 
least three withdrawal symptoms (Daniel et al., 2007; Ussher et al., 2009) and/or 
the composite MPSS score pre- to post-exercise (Everson et al., 2008). Two of 
these studies (Everson et al., 2008; Ussher et al., 2009) compared the effects of 
exercise to a passive sitting condition and found significant interaction (Time x 
Condition) effects. Ussher and colleagues (2009) found that a 10-minute bout of 
isometric exercise reduced levels of irritability, restlessness, and difficulty 
concentrating, as well as tension and stress. Everson and colleagues (2008) 
found that those cycling for 10 minutes at a moderate intensity (40 to 59% HRR) 
reported lower composite MPSS scores at the 5-minute mark compared to those 
sitting passively. However, pairwise comparisons revealed the vigorous-intensity 
(60 to 85% HRR) cycling condition reported significantly higher composite MPSS 
scores during exercise than the passive control.  
 The acute exercise and temporary smoking cessation literature is 
encouraging. A single bout of exercise has shown to consistently alleviate 
cigarette craving, and at times withdrawal symptoms. Therefore, future research 
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should continue to investigate the mediating mechanisms through which exercise 
exerts its acute effects.  
 
Possible Mechanisms of Acute Exercise Effects 
 As previously mentioned, the effect of acute exercise on craving has 
yielded more conclusive evidence than on withdrawal symptoms. Therefore, 
greater efforts have been devoted towards explaining the exercise-craving 
relationship. Understanding the mechanisms by which exercise influences 
craving will not only substantiate the causality of this relationship, but also 
provide insight for developing interventions that maximize craving relief (Taylor et 
al., 2007). The proposed mechanisms that will be reviewed below have been 
categorized into affect, biological, and cognitive hypotheses (Hassova et al., 
2013, 2014; Roberts et al., 2012; Taylor et al., 2007). 
 Affect hypotheses. According to the circumplex model of affect (Russell, 
1980), affective states are thought to arise from two dimensions: valence 
(pleasure-displeasure continuum) and arousal. Smoking cigarettes and exercise 
are two behaviours that influence both of these dimensions. For example, 
smokers report decreases in arousal and increases in emotional stress during 
periods of temporary abstinence. However, both of these levels return to normal 
values upon smoking a cigarette (Steptoe & Ussher, 2006). Furthermore, 
increases in affective valence (Ekkekakis, Parfitt, & Petruzzello, 2011) and 
activation (i.e., arousal; Reed & Ones, 2006) have been shown to occur following 
a single bout of exercise. Therefore, it has been proposed that changes in affect 
resulting from a bout of exercise may mediate its effect on cravings (Taylor et al., 
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2007). In a seminal study, Taylor and colleagues (2006) showed that the 
moderating effect of acute exercise on craving and withdrawal symptoms was 
mediated only through reduced emotional stress (i.e., self-reported tension). In 
another study, Elibero et al. (2011) found that when positive affect was higher, 
cravings were lower. However, changes in positive affect did not mediate the 
exercise and craving relations. Hassova and colleagues (2014) recently tested 
this hypothesis across the IPD (372 observations) of eight studies. The included 
studies compared the effects of moderate-intensity exercise on cravings and 
dimensions of affect to passive controls. They found the exercise group reported 
higher levels of arousal and positive feelings (valence) post-intervention after 
adjusting for baseline values. This finding suggests that a bout of moderate-
intensity exercise increases positive feelings and arousal in temporarily 
abstaining smokers. However, these changes in affect were not significantly 
associated with post-intervention craving values. In other words, neither arousal 
nor valence appeared to meditate the exercise-craving relationship. Despite 
evidence dismissing arousal and valence as potential mechanisms, other 
constructs of mood and affect still warrant investigation.  
 Biological hypotheses. Due to the brain’s limited-processing capacity, it 
is thought that the additional strain of exercise requires a shift in attention from 
cognitive (i.e., cravings) to somatic (i.e., bodily) thoughts (Acevedo & Ekkekakis, 
2006). This hypothesis was supported by Janse Van Rensberg et al. (2012, 
2009b) who found that exercise reduced activation in areas of the brain 
associated with reward processing and increased activation in default mode 
areas of the brain (i.e., medial rostral prefrontal cortex) in temporarily abstinent 
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smokers. The next step is to test whether this attention-shift mediates the effects 
of exercise on craving. 
 Biological markers, such as cortisol, dopamine, catecholamines, heart rate 
variability (HRV), and nicotine metabolism have also been proposed as potential 
mechanisms of the exercise-craving relationship. Chronic smoking results in 
higher levels of plasma and salivary cortisol, a hormone that helps to cope with 
stress (Baron, Comi, Cryns, Brinck-Johnsen, & Mercer, 1995; Field, Colditz, 
Willett, Longcope, & McKinlay, 1994). These elevated cortisol levels drop after 
the first 2 weeks of quitting smoking (Cohen, al’Absi, & Collins, 2004; Frederick, 
Reus, Ginsberg, Hall, Munoz, & Ellman, 1998; Pomerleau C., Garcia, Pomerleau 
O., & Cameron, 1992; Pomerleau O., Pomerleau C., & Marks, 2000; Steptoe & 
Ussher, 2006). Greater reductions in cortisol have been associated with 
increases in craving and withdrawal (Steptoe & Ussher, 2006), higher levels of 
distress, and predictive of subsequent relapse (Frederick et al., 1998). One 
plausible explanation for this finding is that there is an increase in nicotine 
receptor sensitivity associated with a reduction in cortisol leading to an 
intensification of tobacco craving and withdrawal symptoms (Pomerleau O. & 
Pomerleau C., 1990). It is also possible that the stimulating effects of cortisol may 
contribute to the reinforcing properties of smoking, in which case a dramatic drop 
in cortisol might be distressing for the smoker (Steptoe & Ussher, 2006). Acute 
exercise in healthy humans has been shown to elevate cortisol levels 
(Mastorakos & Pavlatou, 2005). Through extension, exercise may help buffer 
both the desire to smoke and withdrawal symptoms by raising cortisol levels back 
to normal, thus regulating the body’s emotional stress response in the absence of 
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nicotine. Scerbo and colleagues (2010) found that exercising at a vigorous 
intensity resulted in a smaller decline in cortisol levels compared to moderate-
intensity exercise or sitting passively. However, this attenuated drop in cortisol 
did not translate into lower reported cravings by the vigorous-intensity exercise 
condition. This null effect may be due to the short abstinence period (3 hours) 
used, and in turn, producing cravings of only moderate degree. Therefore, the 
role of cortisol in the exercise-craving relationship should be examined using a 
longer abstinence period.  
 The remaining biological mechanisms (dopamine, catecholamines, HRV, 
and nicotine metabolism) are at the early stages of investigation, as described 
below. 1) Animal research has shown that exercise stimulates the release of 
dopamine in the striatum of rats (Hattori, Naoi, & Nishino, 1994); which may 
mimic the effects of nicotine on the mesolimbic pathway. However, research has 
not yet confirmed that exercise increases dopamine in the human brain (Taylor et 
al., 2007). 2) The presence of nicotine stimulates the release of adrenaline and 
noradrenaline, two catecholamines partially responsible for tobacco’s mood-
altering effect. As smoking increases levels of circulating adrenaline and 
noradrenaline (Laustiola, Kotamäki, Lassila, Kallioniemi, & Manninen, 1991), 
quitting smoking decreases both (Ward et al., 1991). A single bout of exercise 
has shown to increase the concentration of circulating adrenaline and 
noradrenaline (Richter & Sutton, 1994), which may explain the effect of exercise 
on craving. 3) Heart rate variability has shown to decrease with habitual smoking 
(Lucini, Bertocchi, Malliani, & Pagani, 1996; Niedermaier et al., 1993) and 
increase 4 to 6 weeks after cessation (Stein, Rottman, & Kleiger, 1996). The 
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effect of acute exercise on HRV for smokers is unknown. However, acute 
exercise may expedite this process and produce immediate increases in HRV, 
which in turn, may positively affect craving and withdrawal symptoms. 4) The 
speed at which an individual metabolizes nicotine influences smoking behaviour 
(e.g., number of cigarettes consumed per day) as well as the intensity and 
frequency of cravings experienced during periods of abstinence (Kubota et al., 
2006; Lerman et al., 2006; Schnoll et al., 2009). The role of nicotine metabolism 
should be examined as it may influence the amount of craving relief exercise is 
capable of providing (e.g., may be less effective for smokers with a high nicotine 
metabolism). 
 Cognitive hypotheses. It was once suggested that the cognitive 
demands required to engage in exercise might distract individuals from thoughts 
pertaining to craving. However, the distraction hypothesis seems doubtful–as 
explained by Taylor and colleagues (2007). For one, exercise that requires 
minimal cognitive demands, such as walking, has shown to attenuate craving to a 
similar degree as vigorous-intensity exercise that demands greater resources 
(Scerbo et al., 2010). In addition, if exercise served as a distractor, one would 
expect its effect to dissipate once exercise stopped. However, this is not the 
case, as reductions in craving have shown to last 50 minutes post-exercise 
(Taylor & Katomeri, 2007). For these reasons alone, distraction does not appear 
to be a significant contributor to the effects of exercise on craving. Another 
cognitive mechanism that has been tested is treatment expectations. Patients’ 
expectancy beliefs have been shown to influence treatment outcome in various 
psychotherapies, where individuals with higher expectations experience greater 
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treatment benefits (Constantino, Arnkoff, Glass, Ametrano, & Smith, 2011). Two 
studies (Daniel et al., 2007; Harper, Fitzgeorge, Tritter, & Prapavessis, 2013) 
examined if smokers’ treatment expectations towards exercise influenced its 
effectiveness. Both studies revealed that expectancy levels (hi vs. low) did not 
correspond to the magnitude of symptom relief reported pre- to post-exercise.  
 
Combining Acute Exercise with a Nicotine Lozenge 
 Ample research has confirmed that a single dose of exercise or nicotine 
consumed through a lozenge can effectively alleviate craving, and at times, 
withdrawal symptoms. Although both monotherapies have shown to produce 
greater relief compared to placebos, the adverse symptoms of nicotine 
deprivation persist and unfortunately cause the majority of individuals to return to 
smoking. Implementing these monotherapies together may provide additive relief 
and minimize cravings that linger.  
 Combining monotherapies with distinct mechanisms of action or 
therapeutic pathways has the potential to yield additive benefit (Ebbert, Hays, & 
Hurt, 2010). Apart from the dopamine hypothesis, the proposed mechanisms of 
acute exercise differ from the process by which the nicotine lozenge exerts its 
effect. Therefore, consuming a nicotine lozenge in adjunct with exercise may 
produce greater reductions in craving and withdrawal symptoms. To date, only 
one study has examined the acute effects of combining exercise and NRT on 
craving and withdrawal symptoms (Harper, Fitzgeorge, Tritter, & Prapavessis, 
2012). In a 14-week exercise-aided NRT cessation program, Harper and 
colleagues (2012) found female quitters on the nicotine patch reported a 
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decrease in craving and withdrawal symptoms after a bout of moderate-intensity 
exercise. Significant reductions in craving pre- to post-exercise were found at all 
three assessment points of the program: 1) Week 5 (1 week after quitting while 
on the 21 mg NRT dose); 2) Week 11 (7 weeks after quitting while on the 14 mg 
NRT dose); 3) Week 13 (9 weeks after quitting while on the 7 mg NRT dose). In 
regards to withdrawal symptoms, significant reductions in psychological and 
sedation symptoms were shown at Week 5 and 11, but not at Week 13. 
Significant increases in physical symptoms were found at Week 5 and 11, but not 
at Week 13. No significant change in appetite was evident at any time point. In 
summation, Harper and colleagues found that exercise provided additional 
symptom relief while on an NRT. Although these findings are encouraging, it 
cannot be said for certain that these reductions in craving and withdrawal 
symptoms are specifically related to exercise because there was no control 
condition solely receiving the NRT patch. To validate this work, a more robust 
methodology must be used that compares the combined treatment to a control 
condition. Furthermore, the steady-release of nicotine from the transdermal patch 
alleviates background cravings; hence the instantaneous effect of both a nicotine 
lozenge and acute exercise on episodic cravings in recently abstinent smokers 
remains unknown.  
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Purpose and Hypothesis 
 Purpose. The purpose of the present study was to examine whether an 
acute bout of moderate intensity exercise provides additional craving (primary 
outcome) and withdrawal (secondary outcome) relief to the NRT lozenge in 
recently quit smokers.  
 Hypothesis. It was hypothesized that participants in the treatment 
condition (acute exercise and nicotine lozenge) would report greater reduction in 
craving and withdrawal symptoms than those in the control condition (nicotine 
lozenge alone). 
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Chapter Two: The Current Study 
 
Methods 
 The subsequent methods are reported in accordance with CONSORT 
principles (www.consort-statement.org). The conduct of this study adhered to the 
guidelines outlined in the Declaration of Helsinki (World Medical Association, 
2013) and the Handbook for Good Clinical Research Practice (WHO, 2002). 
Ethical approval was granted from Western University’s Health Sciences 
Research Ethics Board (#103508; Appendix A). All participants read the Letter of 
Information (Appendix A), had his/her questions answered, and signed a Consent 
Form (Appendix A) prior to participation in the study.  
 
Design 
 This research study used a two-group randomized controlled trial design. 
Randomization was accomplished using a computer-generated numbers table. 
 
Participants 
 Inclusion criteria included: (1) aged 18 to 65 years, (2) smoked a minimum 
of five cigarettes per day, (3) interested in quitting, (4) no contraindications to 
physical activity, and (5) no contraindications to NRT. Exclusion criteria included: 
(1) females who were pregnant, intending on becoming pregnant, or breast-
feeding while in the study and (2) inability to abstain from smoking for a minimum 
of 15 hours without nicotine replacement aids. Thirty participants (Mage = 40.24 
years, SD = 10.36) who satisfied all criteria completed the study and were 
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randomized into one of two conditions: moderate intensity exercise (experimental 
arm) or passive sitting (control arm). Participants included 10 males and 20 
females.  
 
Primary Outcome Measure 
 Craving. Cigarette craving was assessed using the “I have a desire to 
smoke” statement (Tiffany & Drobes, 1991). Desire to smoke was scored on a 7-
point Likert scale, from 1 (strongly disagree) to 4 (neither agree nor disagree), 
and 7 (strongly agree). 
 
Secondary Outcome Measure 
 Withdrawal symptoms. Nicotine withdrawal symptoms were measured 
using the Moods and Physical Symptoms Scale (MPSS; West & Hajek, 2004). 
The MPSS contains five single-items that are believed to be part of the nicotine 
withdrawal syndrome, including depressed mood, irritability, restlessness, 
hunger, and poor concentration. In line with previous acute studies, the hunger 
and depression items were removed because of the short assessment period 
used (e.g., Kotlyar et al., 2007; McRobbie et al., 2010). In addition to the 
withdrawal symptoms described above, the MPSS assesses ratings of strength of 
urges to smoke and time spent with urges to smoke. These two items were also 
excluded because it has been suggested that they may not reflect withdrawal 
symptoms, but rather cigarette craving. The three remaining items were rated on 
a 5-point scale, ranging from 1 (not at all) to 5 (extremely). Separate change 
scores were calculated for each item.  
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Other Measures 
 Demographic and smoking behaviour. The following information was 
collected: age, gender, smoking status (e.g., number of cigarettes smoked per 
day), and smoking history (e.g., number of years smoking regularly, number of 
previous quit attempts). In addition, height (m) and weight (kg) were provided and 
Body Mass Index (BMI: kg/m2) was calculated. 
 Physical activity. The short-form International Physical Activity 
Questionnaire (IPAQ; Craig et al., 2003) was used to measure current levels of 
physical activity. The IPAQ assesses (1) walking, (2) moderate, and (3) vigorous 
physical activities. Participants were asked to estimate the amount of time (in 
minutes) they spent performing each type of physical activity in the previous 7 
days. Time spent sitting was measured as well, however, given that this is an 
indicator of sedentary activity, it was excluded in the present study. Separate 
MET-minutes were computed for each level of physical activity by multiplying the 
MET score of an activity by the minutes performed weekly. The MET scores used 
in the calculation included: (1) walking = 3.3 METs, (2) moderate physical activity 
= 4.0 METs, and (3) vigorous physical activity = 8.0 METs. A total physical 
activity score was computed by summing the MET-minute scores for each 
activity. In line with the recommended scoring protocol, participants’ physical 
activity levels were classified as low, moderate, or high.  
 Cigarette dependence. Perception of cigarette dependence was 
measured using the Fagerström Test for Cigarette Dependence (FTCD; 
Fagerström, 2012), formerly known as the Fagerström Test for Nicotine 
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Dependence (FTND; Heatherton, Kozlowski, Frecker, & Fagerström, 1991). The 
FTCD contains six items that were summed to yield a total score out of 10 points. 
A five-level categorization system was used ranging from very low to very high 
dependence. These classes have been scored as very low (0 to 2), low (3 to 4), 
medium (5), high (6 to 7), and very high (8 to 10). The FTCD has shown high 
internal consistency (α = .64, p < .001) and adequate test-retest reliability (r = .88; 
Pomerleau C., Carton, Lutzke, Flessland, & Pomerleau O., 1994). In the current 
study, the Cronbach’s alpha was slightly below the acceptable level (α = .619), 
however, the mean inter-item correlation was adequate, falling within the range of 
.2 to .4 (Briggs & Cheek, 1986). 
 
Intervention 
 Moderate intensity exercise. The experimental condition completed a 
single bout of moderate intensity exercise. The session entailed a 2-minute 
warm-up, 15 minutes of moderate-intensity exercise, and a 3-minute cool-down 
on a Woodway PPS treadmill (Woodway, Waukesh, WI). Moderate intensity was 
defined as 45 to 68% of heart rate reserve (HRR; Karvonen, Kentala, & Mustala, 
1957). Heart rate reserve was calculated using the formula: maximum heart rate 
(HRmax = 220 − age) − resting heart rate (HRrest). Resting heart rate was taken at 
Visit 1 because values can drop approximately 8.5 beats per minute upon 11 to 
15 hours of abstinence (Perkins, Epstein, Stiller, Marks, & Jacob, 1989). 
Therefore, using HRrest values collected prior to quitting provided a more accurate 
indicator of a normal heart rate. The calculation for 45% HRR was: [(HRmax − 
HRrest) × .45] + HRrest. The calculation for 68% HRR was: [(HRmax − HRrest) × .68] 
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+ HRrest. Heart rate was monitored using the Polar RS100 heart rate device. The 
researcher controlled the incline and speed of the treadmill to ensure that 
participants were exercising in their target heart rate range. 
 Passive sitting. The control condition sat alone in a laboratory room for 
20 minutes and had minimal contact with the researcher. Participants were 
allowed to read if they desired. 
 
Procedure 
 Male and female smokers from London, Ontario who were interested in 
quitting were recruited through several sources. Advertisement was exhibited in 
local newspapers, posters were placed at medical clinics, and a mass e-mail was 
sent to students of Western University and employees of the Middlesex London 
Health Unit (Appendix A).  
 Participants were initially screened for eligibility criteria by telephone or e-
mail. Screening questions pertained to age (i.e., between 18 and 65 years), 
smoking status (i.e., number of cigarettes smoked per day), contraindications to 
NRT or exercise (i.e., capable of walking on a treadmill for 20 minutes at a 
moderate intensity), and for females, current pregnancy or breast-feeding 
statuses. For those eligible and interested, a first visit was scheduled where initial 
screening was confirmed and the Physical Activity Readiness Questionnaire 
(PAR-Q; Canadian Society for Exercise Physiology [CSEP], 2002) was 
completed. Participants who answered “yes” to any question on the PAR-Q were 
ineligible to participate. The study required participants to come to the Exercise 
and Health Psychology Laboratory (EHPL, www.ehpl.uwo.ca) at the University of 
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Western Ontario (London, Ontario) for two sessions, before (Visit 1) and after 
quitting (Visit 2). See Figure 2 for a flow diagram of participants. 
 Participants verified their smoking status at Visit 1 using the piCO+™ 
Smokerlyzer® carbon monoxide (CO) monitor (Bedfont Scientific, USA). In line 
with previous research (Faulkner et al., 2010), a breath CO reading greater than 
10 parts per million (ppm) was considered the threshold for inclusion in the study. 
Resting heart rate was collected as well. Participants then completed the 
following questionnaires: (1) demographic and smoking behaviour, (2) IPAQ 
(Craig et al., 2003), (3) FTCD (Fagerström, 2012). All questionnaires can be 
found in Appendix B. Visit 1 took approximately 45 minutes to complete. 
 Visit 2 was scheduled within 1 week of the initial visit. Participants quit 
smoking cigarettes and refrained from using nicotine products 15 hours prior to 
the second visit. Upon arriving at the laboratory, participants provided another 
breath carbon monoxide (CO) sample to confirm their smoke-free status. A 
concentration reading of less than 6 ppm was deemed acceptable (as used in 
previous research). Participants who were unable to obtain a reading of less than 
6 ppm were rescheduled for a second attempt. Those participants unable to 
abstain from cigarettes or nicotine products for the rescheduled appointment 
were deemed ineligible for the study. Once abstinence was confirmed, 
participants’ heart rates were collected and questionnaires pertaining to cigarette 
craving (i.e., desire to smoke; Tiffany & Drobes, 1993) and nicotine withdrawal 
symptoms (i.e., Mood and Physical Symptoms Scale; West & Hajek, 2004) were 
completed. Those who reported craving scores of 1 or 2 (out of 7) were excluded 
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because these baseline values were too low to demonstrate a substantial 
decline. 
 All eligible participants were then randomized to the experimental or 
control condition and received a single dosage of the 2 mg NICORETTE® 
lozenge. The researcher instructed the participant to place the lozenge in his/her 
mouth and let it dissolve (approximately 20 minutes), occasionally moving the 
lozenge from one cheek to the other without chewing or swallowing it.  
 Immediately after administering the lozenge, participants commenced the 
20-minute treatment they were allocated to (i.e., moderate intensity exercise or 
passive sitting). Cigarette craving and nicotine withdrawal symptoms were 
assessed during treatment (at 10 and 20 minutes). Following treatment, both 
conditions sat passively for 40 minutes. Post-treatment craving and withdrawal 
symptoms were assessed four times at 10-minute intervals. See Table 2 for the 
schedule of measures. After completing these assessments, the researcher 
provided participants with a set of smoking cessation aids that included 27 2 mg 
NICORETTE® Lozenges (expected to last 2 to 3 days), the Forever Free™: A 
Guide To Remaining Smoke Free, and direct access to the Smokers Help Line 
(1-877-513-5333). In addition, participants were invited to use the EHPL exercise 
facility over the next two weeks and were offered $50.00 of compensation. Visit 2 
took approximately 90 minutes to complete. 
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Table 2 
 
Schedule of Measures 
Note. CO = carbon monoxide; PAR-Q = Physical Activity Readiness 
Questionnaire; IPAQ = International Physical Activity Questionnaire; FTCD = 
Fagerström Test for Cigarette Dependence; MPSS = Mood and Physical 
Symptoms Scale. 1 = Pre-quit (Visit 1) 2 = Baseline (Visit 2), 3 = 10-min of 
treatment, 4 = 20-min of treatment, 5 = 10-min post-treatment, 6 = 20-min post-
treatment, 7 = 30-min post-treatment, 8 = 40-min post-treatment). 
 
 
 
 
 
 
 
 
 
Variable 1 2 3 4 5 6 7 8 
Expired CO X X       
PAR-Q X        
Demographic 
& smoking 
behaviour 
 
X 
       
IPAQ X        
FTCD X        
Heart rate X X X X X X X X 
Craving  X X X X X X X 
MPSS  X X X X X X X 
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1 
2 
3 
4 
5 
6 
7 
1 2 3 4 5 6 7 
C
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vi
ng
 
Time 
Lozenge & Exercise 
Lozenge alone 
 Pilot sample. A pilot sample (n = 10) was used to determine the optimal 
timing of administering the lozenge and commencing exercise to examine its 
additive effect. Previous research shows that maximum blood nicotine levels are 
reached 25 (McEwen et al., 2008) and 30 minutes (Kotlyar et al., 2007) after 
administering a lozenge. Exercise has shown a more rapid effect on craving, with 
reductions occurring almost immediately after onset. To account for the potential 
lag of the lozenge, a sequential approach was initially used where the 
experimental condition started exercising 10 minutes after administering the 
lozenge. However, preliminary data showed that the lozenge reduced cravings as 
early as 10 minutes after product placement (Figure 1). Therefore, the protocol 
was altered so the exercise and lozenge were administered simultaneously. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pilot sample’s craving relative to time (1 = baseline, 2 = 10-min of 
treatment, 3 = 20-min of treatment, 4 = 10-min post-treatment, 5 = 20-min post-
treatment, 6 = 30-min post-treatment, 7 = 40-min post-treatment). Error bars 
represent standard errors. 
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Sample Size Calculation 
 Muramoto and colleagues (2003) found that a single nicotine lozenge 
elicited a 1.43-point reduction in craving (desire to smoke) assessed on a 7-point 
scale. Roberts and colleagues (2012) calculated a weighted mean difference 
between exercise and control conditions of -1.90 points on the desire to smoke 
scale, in favour of exercise. If the effects of the nicotine lozenge and exercise 
were 100% additive, it would be expected that participants receiving both 
exercise and the nicotine lozenge would experience a larger reduction in craving 
(experimental mean = 3.33, SD = 1.0) compared to those receiving the nicotine 
lozenge alone (control mean = 1.43, SD = 1.0). Hence, in order to be adequately 
powered (power = .99) to detect this difference with the alpha set at .05, a sample 
size of 30 smokers was needed (SamplePower 3, IBM-SPSS). 
 
Statistical Analyses 
 Fidelity check (exercise). A one-way analysis of covariance (ANCOVA) 
was conducted to compare the groups’ heart rate data collected after 20 minutes 
of treatment. Heart rate data collected immediately prior to treatment (i.e., 
baseline) were used as the covariate in this analysis.  
 Group equivalency. One-way analysis of variances (ANOVAs) and Chi-
square tests were used to determine if any differences existed between groups 
for the following data: (a) demographic and smoking behaviour variables 
assessed at Visit 1 and (b) baseline (pre-treatment) craving and withdrawal 
symptoms scores and CO levels assessed at Visit 2.  
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 Primary and secondary outcome analyses. A series of 2 (Condition: 
moderate intensity exercise vs. passive sitting) × 7 (Time: baseline, 10-min of 
treatment, 20-min of treatment, 10-min post-treatment, 20-min post-treatment, 
30-min post-treatment, 40-min post-treatment) repeated measures ANOVAs were 
used to determine whether group differences could be seen across time for 
primary (i.e., craving) and secondary outcomes (i.e., restlessness, irritability, and 
poor concentration). As recommended by Thomson, Nelson, and Silverman 
(2005), significant interactions were described and main effects were only 
reported when no significant interaction was found.  
 Bivariate correlations were conducted on the variables of interest (i.e., 
craving, irritability, restlessness, and poor concentration). Standardized residual 
change scores were calculated for each variable using regression analysis, 
inputting the pre-treatment (baseline) value as the independent variable and the 
20-min treatment value as the dependent variable (Schutz, 1989). The resulting 
residual or change score represents the degree of change over time, 
independent of the baseline value (Sallis, Alcarez, McKenzie, & Hovell, 1999).  
 The level of significance was accepted at p < .05 for all tests (Tabachnick 
& Fidell, 1996). Effect sizes (ηρ2, phi) accompany all reported findings. Data were 
analyzed using IBM SPSS Statistics (Version 21). 
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Results 
 
Treatment of Data  
 Missing data. A pairwise deletion method was used to treat missing data. 
Ten data points were missing from Visit 1: one for age, one for height, two for 
weight, two for BMI, and four for the number of previous quit attempts. Two 
participants (one control, one intervention) were missing complete heart rate data 
collected at Visit 2.  
 Outliers. A boxplot technique was used to identify outliers. A datum point 
was considered an outlier if it extended more than 1.5 box-lengths from the edge 
of the box and an extreme outlier if it extended more than three box-lengths. Ten 
outliers were found at Visit 1: two for weight, two for BMI, one for CO level, four 
for number of quit attempts, and one for number of cigarettes smoked per day. 
No outliers were found at Visit 2. Outliers and extreme outliers were removed 
from the final data set. 
 Assumptions of statistical techniques. The following assumptions were 
satisfied in the present study. 1) The dependent variables assessed were interval 
or ratio (continuous). 2) A random sample from the population was used to obtain 
the data. 3) Each observation or measurement was independent from, or not 
influenced by, any other observation or measurement.  
 The assumption of normality was checked for the ANOVAs and ANCOVA. 
Normality was assessed in part using skewness and kurtosis values and 
histograms were used to check the shape of the distribution. The Kolmogorov-
Smirnov statistic was also used to assess normality, where a significant value of 
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less than .05 indicated a violation of this assumption. These tests did not violate 
normality.  
 The assumption of homogeneity of variance was checked for the ANOVAs 
and ANCOVA using the Levene’s test. A value of less than .05 was used to 
signify a violation of this assumption. No violations were found.  
 The assumption of homogeneity of intercorrelations was assessed for the 
repeated measures ANOVAs using Box’s test of equality of covariance matrices. 
A significant value of less than .001 implied a violation of this assumption. 
Measures of poor concentration and restlessness violated this assumption, 
however, this was disregarded because the conditions were equal in size (n = 15; 
Hakstian, Roed, & Lind, 1979). 
 The assumption of circularity was assessed for the repeated measures 
ANOVAs using Mauchly’s test of sphericity. A significant value of less than .05 
was used as an indicator of a violation of this assumption. Measures of craving, 
poor concentration, restlessness, and irritability were significant (p < .05). 
Therefore, Multivariate statistics were reported to account for these violations 
(Stevens, 1996). 
 In regards to the bivariate correlations, the assumptions of linearity and 
homoscedasticity were checked through visual inspection of the distribution of 
data points in the scatterplots. No violations of assumptions were identified.  
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Figure 2. Flow of participants through the study. 
 
 
Visit 2 
(n = 35) 	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Excluded (n = 5) 
   CO > 6 (n = 1) 
   Craving < 3 (n = 4) 
Visit 1 
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Analyzed 
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Fidelity Check 
 After adjusting for pre-treatment values, those exercising (n = 14, M = 
107.57, SD = 6.97) had a significantly higher heart rates after 20 minutes of 
treatment compared to those sitting passively (n = 14, M = 79.50, SD = 18.18), F 
= 105.42, p < .001, ηρ2 = .81. All 14 participants in the exercise condition with 
complete heart rate data adhered to the moderate intensity prescription (45 to 
68% HRR) while those in the control condition remained below this threshold. 
 
Group Equivalency at Baseline 
 Demographic and smoking behaviour information is shown in Table 3. 
One-way ANOVAs revealed no significant group differences for age, F(1, 27) = 
0.64, p = .432, ηρ2 = .02, weight, F(1, 24) = 0.16, p = .690, ηρ2 = .01, height, F(1, 
27) = 1.18, p = .287, ηρ2 = .04, and BMI, F(1, 24) = 0.99, p = .328, ηρ2 = .04. Chi-
square tests indicated no significant group differences for gender, χ² (1, n = 30) = 
1.35, p = .245, phi = -.28, or level of physical activity, χ² (1, n = 30) = 3.98, p = 
.140, phi = .36. 
 No significant group differences were found for the following smoking 
behaviour variables assessed at Visit 1: CO level, F(1, 27) = 3.28, p = .081, ηρ2 = 
.11, number of cigarettes smoked daily, F(1, 27) = 0.18, p = .673, ηρ2 = .01, 
number of years smoked, F(1, 28) = 0.10, p = .757, ηρ2 = .00, Fagerström Test for 
Cigarette Dependence score, F(1, 28) = 0.93, p = .343, ηρ2 = .03, number of 
previous quit attempts, F(1, 20) = 0.81, p = .380, ηρ2 = .04, and seriousness of 
quit attempt, F(1, 28) = 1.16, p = .290, ηρ2 = .04. In addition, the number of 
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participants who had previously used NRT was not significantly different between 
groups, χ² (1, n = 30) = 2.54, p = .111, phi = .36. 
 There was no significant group difference in CO levels collected at Visit 2, 
F(1, 28) = 1.79, p = .192, ηρ2 = .06. No significant group differences were found 
for baseline (pre-treatment) craving, F(1, 28) = 0.29, p = .595, ηρ2 = .01, irritability, 
F(1, 28) = 0.89, p = .353, ηρ2 = .03, restlessness, F(1, 28) = 0.12, p = .734, ηρ2 = 
.00, or poor concentration, F(1, 28) = 0.03, p = .871, ηρ2 = .00, assessed at Visit 
2. 
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Table 3 
Demographic and Smoking Behaviour Variables 
Note. BMI = Body Mass Index; IPAQ = International Physical Activity 
Questionnaire; CO = carbon monoxide; FTCD = Fagerström Test for Cigarette 
Dependence; NRT = Nicotine Replacement Therapy 
 
 
 
 
 
 
 Exercise Condition  Control Condition 
Variable     M SD %      M   SD % 
Demographic:        
   Age   38.64 8.25     41.73 12.10  
   Gender (male)   20    46 
   Weight (kg)   85.86 7.83     87.71 14.40  
   Height (cm) 176.79 6.38   173.87   7.95  
   BMI (kg/m2)   27.42 3.75     28.86   3.59  
   Physical activity (IPAQ)        
     High   33    27 
     Moderate   20    53 
     Low   47    20 
Smoking behaviour:        
   Visit 1 CO level   16.27 6.24     20.64   6.78  
   Visit 2 CO level     4.87 1.81       5.67   1.45  
   Number of cigarettes per day   18.23 8.34     17.07   6.04  
   Number of years smoking   22.87 6.42     24.00 12.50  
   FTCD     4.13 2.50       4.93   2.02  
   Number of quit attempts     2.50 1.78       3.17   1.70  
   Previously used NRT   47    13 
   Seriousness of quit attempt     8.73 2.34       9.43   0.90  
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Main Analyses  
 Craving (primary outcome). A significant condition by time interaction 
effect was found for desire to smoke, F(6, 23) = 2.70, p = .039, Wilks’ Λ = .59, ηρ2 
= .41. Both groups demonstrated a decrease in craving over time; however, the 
exercise condition’s was of a greater magnitude (Table 4 and Figure 3). 
 Withdrawal symptoms (secondary outcomes). No significant condition 
by time interaction effects were found for restlessness (Table 5 and Figure 4), 
F(6, 23) = 1.97, p = .112, Wilks’ Λ = .66, ηρ2 = .34, irritability (Table 6 and Figure 
5), F(6, 23) = 0.70, p = .653, Wilks’ Λ = .85, ηρ2 = .15, or poor concentration 
(Table 7 and Figure 6), F(6, 23) = 0.91, p = .508, Wilks’ Λ = .81, ηρ2 = .19. 
However, significant time effects were found for restlessness, F(6, 23) = 2.61, p = 
.044, Wilks’ Λ = .60, ηρ2 = .41, and irritability, F(6, 23) = 3.29, p = .017, Wilks’ Λ = 
.54, ηρ2 = .46, with both conditions demonstrating reductions in scores from 
baseline. While ratings of poor concentration decreased from baseline in both 
conditions, no significant time effect occurred, F(6, 23) = 2.47, p = .055, Wilks’ Λ 
= .61, ηρ2 = .39. 
 Correlations. Of the craving and withdrawal constructs, residual change 
scores in restlessness, irritability, and poor concentration were found to be 
significantly and positively correlated with one another (Table 8).  
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Table 4 
Means, Standard Deviations, and 95% Confidence Intervals for Craving Before, 
During, and After Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Exercise Condition  Control Condition 
Time M SD 95% CI  M SD 95% CI 
Baseline 5.67 1.11 [5.13, 6.21]  5.87 0.92 [5.33, 6.41] 
10-min of treatment 3.87 1.51 [3.13, 4.61]  4.93 1.28 [4.19, 5.67] 
20-min of treatment  2.93 1.44 [2.11, 3.76]  3.67 1.68 [2.84, 4.49] 
10-min post 2.67 1.35 [1.85, 3.49]  3.47 1.73 [2.65, 4.29] 
20-min post 2.80 1.08 [2.02, 3.58]  3.27 1.79 [2.48, 4.05] 
30-min post 2.60 1.24 [1.84, 3.36]  3.20 1.61 [2.44, 3.96] 
40-min post 2.47 1.06 [1.70, 3.24]  3.13 1.77 [2.36, 3.90] 
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Figure 3. Craving relative to time (1 = baseline, 2 = 10-min of treatment, 3 = 20-
min of treatment, 4 = 10-min post-treatment, 5 = 20-min post-treatment, 6 = 30-
min post-treatment, 7 = 40-min post-treatment). Error bars represent standard 
errors.  
 
 
 
 
 
 
 
 
45 
Table 5 
Means, Standard Deviations, and 95% Confidence Intervals for Restlessness 
Before, During, and After Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Exercise Condition  Control Condition 
Time M SD 95% CI  M SD 95% CI 
Baseline 2.33 1.05 [1.77, 2.90]  2.20 1.08 [1.64, 2.76] 
10-min of treatment 1.27 0.59 [0.91, 1.62]  1.87 0.74 [1.51, 2.22] 
20-min of treatment  1.33 0.62 [0.96, 1.70]  1.80 0.77 [1.43, 2.17] 
10-min post 1.20 0.41 [0.85, 1.56]  1.97 0.86 [1.61, 2.32] 
20-min post 1.40 0.51 [1.07, 1.73]  1.90 0.71 [1.57, 2.23] 
30-min post 1.53 0.64 [1.14, 1.93]  1.87 0.83 [1.47, 2.26] 
40-min post 1.60 0.83 [1.18, 2.02]  1.83 0.75 [1.42, 2.25] 
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Figure 4. Restlessness relative to time (1 = baseline, 2 = 10-min of treatment, 3 = 
20-min of treatment, 4 = 10-min post-treatment, 5 = 20-min post-treatment, 6 = 
30-min post-treatment, 7 = 40-min post-treatment). Error bars represent standard 
errors.  
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Table 6 
Means, Standard Deviations, and 95% Confidence Intervals for Irritability Before, 
During, and After Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 Exercise Condition  Control Condition 
Time M SD 95% CI  M SD 95% CI 
Baseline 1.80 0.78 [1.29, 2.31]  2.13 1.13 [1.62, 2.64] 
10-min of treatment 1.27 0.59 [0.94, 1.59]  1.60 0.63 [1.28, 1.92] 
20-min of treatment  1.07 0.26 [0.74, 1.39]  1.60 0.83 [1.28, 1.92] 
10-min post 1.20 0.56 [0.88, 1.52]  1.53 0.64 [1.22, 1.85] 
20-min post 1.27 0.46 [0.88, 1.65]  1.53 0.92 [1.15, 1.92] 
30-min post 1.23 0.42 [0.86, 1.61]  1.53 0.92 [1.16, 1.91] 
40-min post 1.20 0.41 [0.83, 1.57]  1.60 0.91 [1.23, 1.97] 
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Figure 5. Irritability relative to time (1 = baseline, 2 = 10-min of treatment, 3 = 20-
min of treatment, 4 = 10-min post-treatment, 5 = 20-min post-treatment, 6 = 30-
min post-treatment, 7 = 40-min post-treatment). Error bars represent standard 
errors.  
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Table 7 
Means, Standard Deviations, and 95% Confidence Intervals for Poor 
Concentration Before, During, and After Treatment 
 
 
 
 
 
 
 Exercise Condition  Control Condition 
Time M SD 95% CI  M SD 95% CI 
Baseline 2.00 1.13 [1.41, 2.59]  2.07 1.10 [1.48, 2.66] 
10-min of treatment 1.60 0.83 [1.15, 2.05]  1.73 0.88 [1.28, 2.19] 
20-min of treatment  1.60 0.83 [1.16, 2.04]  1.47 0.83 [1.03, 1.91] 
10-min post 1.33 0.49 [0.95, 1.72]  1.67 0.90 [1.28, 2.05] 
20-min post 1.20 0.41 [0.85, 1.55]  1.53 0.83 [1.19, 1.88] 
30-min post 1.20 0.41 [0.92, 1.48]  1.33 0.62 [1.06, 1.61] 
40-min post 1.27 0.59 [0.91, 1.62]  1.47 0.74 [1.11, 1.82] 
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Figure 6. Poor concentration relative to time (1 = baseline, 2 = 10-min of 
treatment, 3 = 20-min of treatment, 4 = 10-min post-treatment, 5 = 20-min post-
treatment, 6 = 30-min post-treatment, 7 = 40-min post-treatment). Error bars 
represent standard errors.  
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Table 8 
Correlations Between Residuals for Craving and Withdrawal Symptoms 
 
 
 
 
 
 
 
 
 
* p < .05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measure 1       2       3   4 
1. Residual craving —  .21 -.10    -.12 
2. Residual restlessness  —    .51*      .47* 
3. Residual irritability   —      .68* 
4. Residual poor concentration                 — 
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Chapter Three: Discussion 
 
 The present study examined whether an acute bout of moderate-intensity 
exercise produced additional cigarette craving (primary outcome) and withdrawal 
(secondary outcome) relief to the nicotine lozenge in the initial 15 hours of 
abstinence for smokers undergoing a real-life quit attempt. This randomized 
controlled trial involved two conditions, both of which consumed a nicotine 
lozenge and engaged in either an acute bout of moderate intensity exercise or 
sat passively. Craving and withdrawal symptoms (i.e., restlessness, irritability, 
and poor concentration) were assessed before (baseline), during (10 and 20 
minutes), and after (10, 20, 30, and 40 minutes) treatment at 10-minute intervals. 
 
Craving 
 Findings from the present study indicate that exercising at a moderate 
intensity reduces cigarette cravings to a greater degree than sitting passively in 
recently quit smokers who are consuming a nicotine lozenge. Both groups 
showed decreases in craving from baseline, however, the experimental condition 
(acute exercise and nicotine lozenge) had lower scores at each assessment point 
compared to the control condition (nicotine lozenge alone). 
 The largest reduction in craving occurred during the 20-minute treatment 
period for both conditions (i.e., steepest slopes in Figure 3). From baseline to 10 
and 20 minutes of treatment, the experimental condition had decreases of 31.7% 
and 48.3%, respectively, and the control condition dropped by 16.0% and 37.5%, 
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respectively. Thus, the experimental condition had a 10.8% larger reduction in 
craving than the control at the end of treatment. 
 Craving scores for both conditions continued to decrease following 
treatment. However, these reductions were smaller in magnitude than those 
reported during treatment. From baseline to post-treatment assessment points 
(i.e., 10, 20, 30, and 40 minutes), the experimental condition had respective 
declines of 52.9%, 50.6%, 52.9%, and 56.4%, whereas the control condition had 
reductions of 40.9%, 44.3%, 45.5%, and 46.7%, respectively. Thus, the 
difference at 40-minutes post-treatment favoured the experimental condition by 
10.3%. This is comparable to the 10.8% difference that was found immediately 
after treatment. Therefore, the benefit of supplementing the nicotine lozenge with 
exercise was preserved even after treatment stopped. 
 The results of the present study substantiate the work of Harper and 
colleagues (2012) who found that acute exercise alleviated cigarette cravings in 
smokers on the nicotine patch. Specifically, participants reported 20.8%, 16.7%, 
and 22.7% reductions in cravings following exercise while having quit and been 
on the patch for 1, 7, and 9 weeks, respectively. The reduction in craving scores 
reported in the present study is twice as large (48.3%) as those found by Harper 
et al. This may be because the two studies differed in their durations of 
abstinence and NRT products used. It has been suggested that cravings are 
most intense during the initial days of abstinence. Hence, recently quit smokers 
(i.e., 15 hours of abstinence in the present study) should report higher baseline 
cravings, and in turn, greater change scores, than those who have been smoke-
free for days or weeks (i.e., Harper et al.’s study). The steady-release of nicotine 
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from the transdermal patch alleviates background cravings, while the 
instantaneous effect of both the nicotine lozenge and exercise target episodic 
cravings. Therefore, a larger reduction in episodic craving would be expected in 
the present study because two acute cessation aids were used that provide 
immediate relief. Nonetheless, both studies provide strong evidence that an acute 
bout of exercise can supplement, and is not redundant to, the craving relief 
experienced with NRT products. 
 An interesting inference can be drawn by the difference in groups’ change 
scores reported in the present study. On the 7-point craving scale, the 
experimental and control groups had respective decreases of 2.74 and 2.20 
points from before to immediately after treatment. This equates to a 0.52-point 
difference in favour of the exercise condition. In other words, exercising while 
consuming a nicotine lozenge produced an additional half of a point reduction in 
craving compared to the lozenge alone. Using the same measure of craving, 
Muramoto and colleagues (2003) found the nicotine lozenge resulted in a 1.43-
point decrease and, as previously mentioned, Roberts et al. (2012) and Hassova 
et al. (2013) found respective 1.90 and 2.04 point differences in change scores 
that favoured the exercise groups (vs. passive controls). Based on these findings, 
if the effects of exercise and the nicotine lozenge were 100% additive, a 2.0-point 
difference in change scores between the experimental (exercise and nicotine 
lozenge = 3.43) and control groups (nicotine lozenge alone = 1.43) would have 
been expected. While this would have been optimal, the difference found in the 
present study was approximately one-quarter in size (0.52). Nevertheless, the 
effect produced when exercise was added to the nicotine lozenge was significant.  
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 These findings suggest that acute exercise and the nicotine lozenge are 
functioning, to some extent, through distinct mechanisms. The manner by which 
the nicotine lozenge exerts its effect on cigarette craving is better understood 
than that of exercise. As previously mentioned, NRT products effectively 
suppress cravings by binding to nicotine-deprived nAChRs in the brain that were 
once stimulated by nicotine in cigarettes. In regards to explaining the exercise-
craving relationship, it is unlikely that the aforementioned affect and cognitive 
(i.e., distraction and expectancy) hypotheses hold any merit. However, the 
biological mechanisms (i.e., attention-shifts, cortisol, dopamine, catecholamines, 
heart rate variability, and nicotine metabolism) that have been proposed seem 
plausible, but have not yet been rigorously investigated. Therefore, future 
research should aim to test these hypotheses to gather a better understanding of 
the acute effects of exercise.  
 While the benefit of combining the two modalities has been demonstrated 
in a laboratory setting, the ecological validity of this finding must be further 
examined. For example, perceived environmental and psychological barriers may 
discourage smokers from using this combined treatment approach in a 
naturalistic setting. Therefore, using ecological momentary assessment (i.e., 
smart-phone application), researchers could gather information pertaining to the 
challenges smokers encounter to incorporating exercise with the nicotine lozenge 
during a real-life craving episode. From there, tailor-made feedback statements 
could be developed that help mitigate specific obstacles. These statements could 
then be delivered through the smart-phone application when individuals are at-
risk of relapse and experiencing intense cravings.  
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Withdrawal Symptoms  
 The present study demonstrates that symptoms of restlessness, irritability, 
and poor concentration, which are heightened in nicotine-deprived smokers, can 
be effectively ameliorated by a single dose of a nicotine lozenge. Although no 
significant group by time interaction effects were found, those who exercised 
while consuming the nicotine lozenge appeared to have greater reductions in 
restlessness and irritability compared to those who sat passively. 
 Restlessness. Whether individuals consumed the lozenge while 
exercising or sitting passively, decreases in restlessness were found. Hence, a 
single nicotine lozenge can alleviate feelings of restlessness in recently quit 
smokers. While the conditions were not significantly different, the patterns of 
restlessness scores exhibited in Figure 4 are behaving as expected and thus 
worth describing. As hypothesized, the experimental condition had larger 
decreases in restlessness scores compared to the control condition. During 
treatment (baseline to 10 and 20 minutes), the experimental condition’s 
restlessness score decreased by 45.5% and 42.9%, respectively, whereas the 
control condition reported reductions of 15.0% and 18.2%. Therefore, the 
experimental condition had a 24.7% larger decline in restlessness from baseline 
to the end of treatment. This percent difference is larger than that found for 
craving. However, it must be remembered that the absolute reduction in 
restlessness was 1 point for the exercise condition and 0.33 of a point for the 
control condition at the end of treatment. Both of these absolute point reductions 
are much smaller than what was reported for cravings. With the variability scores 
(SD) reported in Table 6, these modest point reductions are likely responsible for 
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the statistical analysis being underpowered (.59) and not reaching significance (p 
= .112). 
 Following treatment, restlessness scores of the experimental group 
increased slightly while those of the control condition remained relatively stable. 
At 10, 20, 30, and 40 minutes post-treatment, the experimental condition reported 
respective decreases of 48.5%, 38.6%, 34.3%, and 31.4%, and the control 
condition had declines of 10.5%, 13.6%, 15.1%, and 16.7%, respectively. As 
shown, the difference between the conditions diminished to 14.7%. Nevertheless, 
the experimental conditioned continued to report lower scores than the control 
condition at each post-treatment time point. Therefore, it appears that the effects 
of exercise augment the reductions in restlessness that occurs with the nicotine 
lozenge. However, the additive effect of exercise begins to subside once 
terminated. 
 Unfortunately, these findings cannot be directly compared to the work of 
Harper and colleagues (2012) because the Shiffman-Jarvik scale (Shiffman & 
Jarvik, 1976) that they used assessed different withdrawal symptoms from the 
MPSS, which was used in the present study. However, Ussher and colleagues 
(2009) did employ the MPSS to examine the effect of 10 minutes of isometric 
exercise on restlessness. They found that the exercise condition had a 
significantly (28%) larger decrease in restlessness score compared to the 
passive control. This finding supports the notion that exercise can effectively 
reduce feelings of restlessness in recently quit smokers, although no NRT 
product was involved.  
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 Irritability. Both conditions showed decreases in irritability scores from 
baseline. Thus, a nicotine lozenge can temporarily alleviate feelings of irritability 
that accompany smoking abstinence. Although no significant interaction effect 
was found, greater reductions in irritability scores occurred with those who 
exercised while consuming the lozenge as opposed to sitting. Relative to 
baseline values, the experimental condition had decreases of 29.4% and 40.6% 
at 10 and 20 minutes of treatment, respectively, while the control condition 
dropped by 25% at both assessment points. Therefore, those who exercised had 
a 15.6% greater reduction at the end of treatment. At 10, 20, 30, and 40 minutes 
post-treatment, the experimental condition had declines of 33.3%, 29.4%, 31.5%, 
and 33.3%, respectively, and the control group remained relatively stable at 
28.1%, 28.1%, 28.1%, and 25.0%. As exhibited with restlessness, the difference 
in reductions diminished (to 8.3%) but continued to favour the experimental 
condition. Overall, supplementing the nicotine lozenge with concurrent exercise 
provides some additional, albeit small and temporary, relief from feelings of 
irritability. 
 While no other research has yet to verify this effect, Ussher and 
colleagues (2009) found that the isometric exercise condition reported greater 
reductions in irritability scores compared to the controls in both a natural (16.0%) 
and laboratory setting (38.8%). Although no NRT was utilized, they did 
demonstrate that feelings of irritability resulting from nicotine withdrawal could be 
significantly alleviated by acute exercise. Until more consistent results emerge for 
restlessness and irritability outcomes, identifying the mechanistic pathways of 
how exercise influences these withdrawal symptoms will have to wait.  
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 Poor concentration. Ratings of poor concentration were shown to 
significantly decrease in both conditions upon implementing the nicotine lozenge. 
No significant interaction effect was found or appeared to be emerging. 
Therefore, it does not seem that an acute bout of exercise augments the effect of 
the lozenge to a notable degree. Relative to baseline values, the experimental 
condition had declines of 20.0%, 20.0%, 33.4%, 40.0%, 40.0% and 36.7% at 
each 10-minute interval and the control condition had declines of 16.2%; 29.0%, 
19.4%, 25.8, 33.4%, and 29.0%. Contrary to expectations, the control condition 
had a larger decline (9.0%) in poor concentration than the exercise condition at 
the end of treatment. This outcome did not endure following treatment, where the 
difference in change scores favoured the experimental group by 7.7%. These 
group differences should be interpreted with caution as the means fluctuated at 
each assessment point and the surrounding error bars were large (Figure 6). 
Unlike restlessness and irritability symptoms, no consistent pattern was found to 
conclude that ratings of poor concentration are reduced to a greater degree when 
exercise is added to the nicotine lozenge.  
 It has been hypothesized that exercise might work to improve 
concentration during periods of nicotine withdrawal by shifting one’s attention 
away from cravings, and in turn, increasing one’s attentional capacity towards the 
task at hand. Ultimately, this would reduce the withdrawal symptom of poor 
concentration (Janse Van Rensburg & Taylor, 2008). Findings pertaining to the 
effect of acute exercise on concentration abilities have been mixed. Daniel and 
colleagues (2009) used the MPSS to assess perceived concentration difficulties 
and found significantly larger reductions among those who exercised versus 
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those who sat passively. Conversely, Janse Van Rensburg and Taylor (2008) 
objectively measured the cognitive performance using a Stroop (1935) colour-
word interference task and found that exercise did not enhance cognitive 
functioning relative to the passive control condition. Nevertheless, the effect of 
combining exercise with NRT on concentration should not be dismissed until a 
more robust and objective measure of cognitive performance is used. 
 
Strengths and Limitations 
 There are a number of strengths to the present study. For instance, the 
subjective assessments were validated, objective measures (i.e., heart rate data, 
CO reader) were used when appropriate, the randomization minimized 
contamination of extraneous variables, and the post-treatment period was 
sufficient in duration (40 minutes) to examine the residual effects of treatment. 
Furthermore, incorporating a pilot sample was advantageous because it exposed 
the optimal timing of administering the two treatment modalities. Lastly, using a 
sample of smokers undergoing a real-life quitting attempt enhanced the 
ecological validity of the present study. The majority of previous studies involve 
temporarily abstaining smokers who are likely to return to smoking. As a result, 
their reported symptoms may not be entirely representative of those experienced 
by real-life quitters.  
 Despite the aforementioned strengths, there are limitations of this study 
that must be acknowledged. For example, the researcher and participants were 
not blinded to their allocated treatment. In addition, the generalizability of these 
findings is limited to smokers who have quit only 15 hours prior. Furthermore, the 
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present trial was conducted in a laboratory setting, and therefore, may not 
translate to the actual environment and situations that quitters will encounter 
during peak episodic cravings. While previous research (i.e., Harper et al., 2012) 
suggests that exercise can still alleviate cravings in those who have been smoke-
free and on the patch for weeks, this cannot be said for certain in the present 
study.  
 
Conclusions 
 Findings from the present study demonstrate that an acute bout of 
exercise provides additional craving relief to the nicotine lozenge in recently quit 
smokers. Therefore, individuals should employ both cessation aids 
simultaneously to maximize reductions in cravings. More research is required to 
untangle the underlying mechanisms through which exercise exerts its effect. 
Furthermore, the feasibility of engaging in a bout of exercise when experiencing 
heightened cigarette cravings in a natural environment must be examined.  
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Recruitment Poster 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QUIT%SMOKING,RESEARCH,STUDY!,
,
PARTICIPANTS,NEEDED,!
The Exercise and Health Psychology Lab at Western University is conducting a study to 
determine the effects of exercise and NICORETTE® Lozenges on craving and 
withdrawal symptoms.   
 
Participants will be asked to come into our laboratory twice, before and after quitting, to 
exercise and complete questionnaires. 
 
To be eligible you must: 
• Be between 18-64 years of age 
• Smoke at least 5 cigarettes per day 
• Not have any other substance dependency issues (e.g. alcohol) 
• Not have any physical limitations that prevent walking 
• Not pregnant, considering becoming pregnant or breast-feeding 
 
All men and women will be provided with a quit-smoking package, including: 
 
 NICORETTE® Lozenges 
 Daily access to our exercise facility for 2 weeks 
 Forever FreeTM: A Guide To Remaining Smoke Free 
 
Participants will be compensated financially for their time 
 
If you are interested in participating or would like to hear more about this study, please 
contact Amelia and take a tab below. !!! freequ
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Recruitment E-mail  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Line: Invitation to Participate in a Quit-Smoking Program 
 
You are being invited to participate in a quit-smoking program that involves quit-
smoking aids, including: NICORETTE® Lozenges, Forever FreeTM: Guide To 
Remaining Smoke Free, and access to our exercise facility for 2 weeks. 
The study requires participants to come into the Exercise and Health Psychology 
Lab (Room 408, Labatt Health Sciences Building) at Western University twice, 
before and after quitting, to exercise and complete questionnaires. If you would 
like more information on this study or would like to receive a letter of information 
about this study please contact the Amelia at the contact information given 
below. 
 
Thank you, 
 
Amelia Tritter 
E-mail: freequitsmokingstudy@gmail.com5
 !
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Letter of Information 
 
 
LETTER OF INFORMATION 
 
Study Title: The effect of exercise on cigarette craving and withdrawal symptoms 
while using a nicotine lozenge.  
 
Principal Study Investigator:  
Harry Prapavessis, Ph.D. (School of Kinesiology, The University of Western Ontario) 
 
Co-Investigator: 
Amelia Tritter, B.A. (School of Kinesiology, Western University) 
 
You are being invited to participate in a research study looking at the effects of exercise 
and nicotine lozenges on craving and withdrawal symptoms in smokers who have 
recently quit. This is a randomized control trial (a type of research study), which includes 
eligible volunteers who choose to take part. Please take your time to make a decision, and 
discuss this proposal with your personal doctor, family members and friends, as you feel 
inclined. The purpose of this letter is to provide you with the information you require to 
make an informed decision on participating in this research. This letter contains 
information to help you decide whether or not to participate in this research study. It is 
important for you to know why the study is being conducted and what it will involve. 
Please take the time to read this carefully and feel free to ask questions if anything is 
unclear or there are words or phrases you do not understand. We are asking you to take 
part because you are an adult between 18 and 64 years of age who smokes. 
 
Purpose of the study 
Exercise and nicotine lozenges have shown to reduce cigarette cravings and withdrawal 
symptoms that are experienced when trying to quit smoking.  
 
The objective of this study is to examine the effects of an acute bout of moderate intensity 
exercise and a nicotine lozenge on smoking cravings and withdrawal symptoms in 
smokers who have recently quit. 
 
Participants 
Sixty participants will be asked to take part in this research. To be eligible to participate, 
you must meet the following criteria: 18 and 64 years of age, smoke a minimum of 5 
cigarettes per day, have not been engaged in a serious quit attempt in the last six months, 
must not be suffering from an illness (e.g. cold) that would affect your typical smoking 
behaviour, do not have a medical condition that prevents you from exercising, not be 
pregnant, intending on becoming pregnant or breast-feeding.  As recommended in the 
NICORETTE® Lozenge label, you are not able to participate if you have had, or are 
aware of having, a heart disease, a recent heart attack, an irregular heartbeat, high blood 
pressure not controlled with medication, a stomach ulcer, or diabetes, and/or are using a 
non-nicotine stop smoking drug or prescription medication for depression or asthma. You 
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must also be able to read and write in English and have a telephone or e-mail account that 
the investigators can contact you at.  
 
Research Procedure 
If you choose to take part in this study, you will be asked to complete three study 
components:  
A) first laboratory session, B) quit smoking, C) second laboratory session.  
The laboratory sessions will be held at the Exercise and Health Psychology Laboratory 
(EHPL) at Western University. The EHPL is located in Room 408 of the Labatt Health 
Sciences Building.  The first laboratory session will take approximately 30 minutes, and 
the second visit will be approximately 90 minutes. 
 
A) First laboratory session 
During your first laboratory session, you will complete a questionnaire package (see Item 
1) and the following information will be collected: weight, height, and breath carbon 
monoxide levels (see Item 2). At the end of your first laboratory session, we will schedule 
your second laboratory session within seven days of your first laboratory session. It is 
within your rights to refuse to answer any questionnaire items and we will honour your 
rights.  
 
B) Quit smoking 
You will be asked to quit smoking 17 hours before your second laboratory visit (see Item 
7).  We will confirm that you have not smoked in the last 17 hours by asking you to 
provide a breath carbon monoxide level (see Item 2). In addition, we will ask you to 
refrain from using nicotine products during these initial 17 hours of quitting. 
 
C) Second laboratory session 
When you arrive for the second lab visit, you will be asked to provide a breath carbon 
monoxide level to confirm abstinence (Item 2).  If the carbon monoxide value shows that 
you are not smoke-free at this time, we will reschedule your appointment.  If at that time 
you again are unable to abstain, you will be ineligible to continue with the study.  You 
will then complete a questionnaire package containing items pertaining to your current 
cigarette cravings and withdrawal symptoms (see Item 3).  After completing the 
questionnaire package, you will be given instructions on how to consume the 2mg 
NICORETTE® Lozenge (Item 4). The researcher will answer any questions you have 
about the product and you will be asked to provide verbal and written confirmation of 
your understanding. After placing the lozenge in your mouth, you will be randomly 
assigned to either sit in a quiet room and read or participate in an exercise session (i.e. 
walk on a treadmill at a moderate intensity) for 30 minutes. Individuals will be 
randomized into study arms using a computer-generated numbers table. You will not be 
able to choose which group you are assigned to and that group allocation will be random, 
therefore, you have an equal chance of getting into either group.  At the 10-minute and 
20-minute marks of having the lozenge in your mouth, you will complete the craving 
questionnaire (Item 5). Immediately after exercising or reading, you will complete 
craving and withdrawal questionnaires (Item 6).  
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In addition, you will be asked to complete this questionnaire package two more times (10 
and 20 minutes post-treatment).  During this time, the researcher will give you a tour of 
the exercise facility and you will be given your quit-smoking package, which includes: 27 
2mg NICORETTE® Lozenges (with instructions), the Forever Free™: A Guide To 
Remaining Smoke Free set of 8 booklets, direct assess to the Smokers Help Line (1-877-
513-5333), and the hours in which the exercise facility will be open for use over the next 
two weeks.  
Experimental description (items 1-6) 
Item 1: Pre-treatment questionnaire package (1st lab visit) 
Time Involvement: 30 minutes 
The questionnaire package will include: demographics information sheet, smoking history 
questionnaire, physical activity questionnaire, nicotine dependence questionnaire, 
cigarette cravings questionnaire and withdrawal symptoms questionnaire.  
 
Item 2: Carbon monoxide assessments (1st and 2nd lab visits) 
Time Involvement: 15 seconds  
We will ask you to breathe into a machine called the Bedfont Smokerlyzer. This machine 
measures the amount of carbon monoxide (CO) as you breathe out. It does not cause any 
harm or discomfort to you. This Smokerlyzer measures how much you have smoked in 
the past several hours. A CO value of less than 6 parts per million will confirm that you 
have temporarily stopped smoking. 
 
Item 3: Baseline & Post-treatment questionnaire package (2nd lab visit) 
Time Involvement: 20 minutes 
The questionnaire package will include: cigarette cravings questionnaire and withdrawal 
symptoms questionnaire 
 
Item 4: Nicotine lozenge (2nd lab visit) 
Time Involvement: 20-30 minutes to dissolve 
We will ask you to place the lozenge in your mouth and occasionally move the lozenge 
from one side of your mouth to the other until completely dissolved. You will be 
instructed to not chew or swallow lozenge; and not eat or drink 15 minutes before using 
or while the lozenge is in your mouth. 
 
Item 5: During-lozenge questionnaire (2nd lab visit) 
Time Involvement: 20 seconds 
We will ask that you complete the craving questionnaire 10 and 20 minutes after placing 
the lozenge in your mouth. 
 
Item 6: Quit smoking  
We ask that you quit smoking at least 17 hours before your second lab visit (17-24 hours). 
 
Risks 
While in the study, you may experience side effects.  Known side effects are listed below, 
but other effects may occur that we cannot predict.  If you are or become pregnant you 
must notify the investigator because smoking and NRT products propose a risk to you and 
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the foetus; therefore, you will be removed from the study.  
 
Exercise: There are some inherent risks of injury associated with exercise participation, 
particularly among people who are not used to exercising. You may, for example, feel 
mild muscle “tightness” or soreness that lasts for a couple of days.  The possible benefits 
associated with exercise may outweigh the potential minor discomfort of beginning a 
supervised, laboratory-based exercise program.  To minimize the physical risks of 
exercise, proper warm-up/cool-down and stretching protocols will be performed by a 
trained exercise counsellor.  Additionally, the exercise program delivered will be tailored 
to your individual fitness level, and modified according to your comfort level.  
Furthermore, you will only be allowed to participate in this exercise program if you 
complete the PAR-Q (Physical Activity Readiness Questionnaire) forms to ensure that it 
is safe for you to begin an exercise program.  The exercise facilitator will be both CPR 
and First Aid trained, and experienced in working with previously inactive populations.If 
any physical or mental risks arise during treatment, The Student Emergency Response 
Team (SERT) will be available to provide immediate assistance. SERT will assist the 
exercise supervisor until the 911 emergency services arrive.  Should you have a minor 
injury, for instance sore knees, or cramped muscles (e.g. a “Charlie horse”), while 
exercising you will receive first aid onsite as required.  A first aid kit and ice packs will 
be available for minor injuries. 
 
Quitting smoking: You may experience withdrawal symptoms during the time you are 
abstaining from cigarettes. Such symptoms may include feeling edgy and nervous, dizzy, 
sweaty, having trouble concentrating, headaches, insomnia, increased appetite and weight 
gain, muscular pain, constipation, fatigue, or having an upset stomach. All of these 
symptoms are common for those who have quit smoking so you should not be alarmed. 
Moderate intensity exercise has been shown to reduce smoking withdrawal symptoms, so 
it could be that those in the moderate intensity exercise treatment condition experience 
relief from some of these symptoms. Another common side effect of quitting smoking is 
that your “smoker’s cough” gets worse for the first few days after you quit. This is your 
body’s way of attempting to rid the lungs of congestion. Your smoker’s cough will 
improve largely if you have become smoke-free for a number of days.  
 
Nicotine Lozenge: The primary side effects of the lozenge include: sore throat, heartburn, 
nausea/indigestion, and hiccups. People who experience irregular heartbeat, severe throat 
irritation, or mouth problems should consult their doctor.  Failing to follow instructions 
can put you in danger of a nicotine overdose. If you are on nicotine lozenges for a long 
period of time, this may increase your risk of experiencing withdrawal symptoms after 
ending treatment. 
 
Benefits 
Your participation may help you and us gain knowledge to shape the development of 
future exercise and smoking cessation programs.  
 
Participation 
Participation in this study is voluntary.  You may refuse to participate, refuse to answer 
any questions or withdraw from the study at any time with no effect on your academic or 
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employment status. If you decide to take part you will be given this Letter of Information 
to keep and be asked to sign the consent form. If you withdraw from the study, you 
maintain the right to request that any data collected from you not be used in the study. If 
you make such a request, all of the data collected from you will be destroyed. Please 
contact the study coordinator, Amelia Tritter, if you wish to withdraw from the study. If 
you are participating in another study at this time, please inform the study researchers 
right away to determine if it is appropriate for you to participate in this study.  
 
New Findings 
If, during the course of this study, new information becomes available that may relate to 
your willingness to continue to participate, this information will be provided to you by the 
investigator (for instance, if a new quit-smoking aid becomes available). 
 
Confidentiality 
We will be collecting information from 60 participants for this study.  All the information 
you provide to the researcher will be kept in the strictest confidence.  You will be 
assigned an identification number and all data collected from you will be recorded and 
stored under this number only. All data will be stored in coded form on computers 
accessible only to research staff in a secure office. A master list matching your personal 
identification (i.e. first and last name) to your participant number will be generated and 
stored in a locked cabinet. The master list will be stored separately from the stored data. 
You will not be identified in any documents relating to the research. No information 
obtained during the study will be discussed with anyone outside of the research team. If 
the results of the study are published, your name will not be used.  
 
Representatives of the Western University Health Sciences Research Ethics Board and 
regulatory bodies (Health Canada) may contact you or require access to your study-
related records to monitor the conduct of the research. If we find information we are 
required by law to disclose, we cannot guarantee confidentiality. We will strive to ensure 
the confidentiality of your research-related records. Absolute confidentiality cannot be 
guaranteed, as we may have to disclose certain information under certain laws.  
 
Compensation 
Free parking will be provided for your visits to the laboratory.  You will be reimbursed 
$5.50 upon arrival at each visit to compensate you for transportation (i.e. bus fare or gas). 
Upon terminating the study, you will be given an additional $39.00. We provide you with 
the majority of compensation at the end of the study because this is where the majority of 
your time will be needed. This fund can be used for future transportation to the laboratory 
if interested in using our exercise facility. In addition, this fund can be used to purchase 
additional nicotine replacement therapy products. 
 
If you have private medical or life insurance, you should check with your insurance 
company before you agree to take part in the study to confirm your participation in this 
study will not affect your insurance coverage and/or access to benefits. 
 
This study is covered by Western University’s insurance policy and if during the course 
of the study, any injury should occur to you, not due to your fault or negligence, all 
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medical expenses necessary to treat such injury will be paid provided: a) you comply at 
all times with the study researcher’s instructions b) you promptly report any such injury 
to the study researchers conducting the study, and c) the expenses are not otherwise 
covered by your provincial health care. Financial compensation for such things as lost 
wages, disability or discomfort due to this type of injury is not routinely available. You 
do not waive any legal rights by signing the consent form. 
 
Alternative treatments 
If you decide not to participate or if you withdraw from the study before it is completed, 
the alternative course of treatment could be to see your family physician for advice on 
how to quit smoking.  Another alternative to the procedures described above is not to 
participate in the study and continue on just as you do now. 
 
Contact person(s) 
If you have any questions about your rights as a research participant or the conduct of the 
study you may contact Dr. David Hill, Scientific Director, Lawson Health Research 
Institute. 
 
This letter is for you to keep.  You will be given a copy of this letter of information and 
consent form once it has been signed. If you have any concerns, please feel free to contact 
one of the researchers below.  You may request the general findings of this research study 
from the researchers after the study is complete.  You do not waive any legal rights by 
singing the consent form. 
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INFORMED CONSENT 
 
 
Study Title: The effect of exercise on cigarette craving and withdrawal symptoms 
while using a nicotine lozenge. 
 
I have read the Letter of Information, have had the nature of the study explained to me 
and I agree to participate.  All questions have been answered to my satisfaction. 
 
 
Please send me the overall conclusions from this trial:    Yes □ No □ 
 
 
I would like to be contacted for other research studies:     Yes □ No □ 
 
 
Consenting Signature: 
 
Participant: ________________________________________________________      
      Please Print Name 
 
 
Participant: ________________________________________________________      
      Please Sign Name 
 
Date:  ___________________ 
 
 
 
 
 
Researcher Signature: 
 
Person obtaining informed consent:    _______________________________________      
        Please Print Name 
 
 
Person obtaining informed consent:    _______________________________________      
                                                                                     Please Sign Name 
 
Date: ___________________ 
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Craving 
 
 
INSTRUCTIONS: Please read the following statement and CIRCLE the number that 
most accurately reflects how you feel in the table underneath. 
 
1. I have a desire to smoke. 
 
Strongly 
disagree 
  Neither 
agree nor 
disagree 
  Strongly 
agree 
1 2 3 4 5 6 7 
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Withdrawal Symptoms 
 
 
Please CIRCLE one number for each of the items below for how you feel RIGHT IN 
THIS MOMENT. 
 
 Not at all Slightly Somewhat Very Extremely 
1. Irritable 1 2 3 4 5 
2. Restless 1 2 3 4 5 
3. Poor concentration 1 2 3 4 5 
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Demographic and Smoking Behaviour Questionnaire 
 
 
First Name:_______________________  Last Name:__________________________ 
 
Address:________________________________________________________________              
     STREET ADDRESS, CITY, POSTAL CODE 
 
Home Phone: ________- _________-_________ 
 
Email Address: ____________________________________@_____________________ 
 
Date of Birth: ________/________/___________               Age: _________ 
 
Gender:   o Male     oFemale        If female, day of menstrual cycle: _________ 
 
Height: __________   Weight: ___________  BMI: ____________ 
 
Please indicate the number of years you have smoked: ________________________ 
 
On average, how many cigarettes do you smoke per day? : ___________________ 
 
How many times have you tried to quit smoking?: _______________________ 
 
Have you tried quitting smoking using Nicotine Replacement Therapy?    o Yes    o No 
 
If yes, please specify the product (e.g. patch, inhaler, lozenge, gum): ________________ 
 
Do you currently smoke any other substance besides cigarettes?      o Yes    o No 
 
If yes, please specify (e.g. marijuana, cigar, pipe, cigarello, hookah):  ________________ 
 
Have you ever smoked any other substance besides cigarettes?    o Yes o No 
 
If yes, please specify (e.g. marijuana, cigar, pipe, cigarello, hookah):  ________________ 
 
Does anyone in your household currently smoke?    o Yes   o No 
 
Do you drink Alcohol?    o Yes    o No      If yes, number of drinks per week? ________ 
 
What is the approximate date and time of the last cigarette you have smoked? 
    
Date:  _______________ Time: _______________ 
 
On a scale from 1 to 10, How serious are you about this quit-attempt?    ___________ 
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International Physical Activity Questionnaire (Short-form) 
 
We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives. The questions will ask you about the time you spent being 
physically active in the last 7 days. Please answer each question even if you do not 
consider yourself to be an active person. Please think about the activities you do at work, 
as part of your house and yard work, to get from place to place, and in your spare time 
for recreation, exercise or sport. 
 
Think about all the vigorous and moderate activities that you did in the last 7 days. 
Vigorous physical activities refer to activities that take hard physical effort and make you 
breathe much harder than normal. Moderate activities refer to activities that take 
moderate physical effort and make you breathe somewhat harder than normal. 
 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
 
The first section is about your work. This includes paid jobs, farming, volunteer work, 
course work, and any other unpaid work that you did outside your home. Do not include 
unpaid work you might do around your home, like housework, yard work, general 
maintenance, and caring for your family. These are asked in Part 3. 
 
1. Do you currently have a job or do any unpaid work outside your home? 
 
 Yes 
 
 No Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you did in the last 7 days as part of 
your paid or unpaid work. This does not include traveling to and from work. 
 
2. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, heavy construction, or climbing up stairs as 
part of your work? Think about only those physical activities that you did for at 
least 10 minutes at a time. 
 
_____ days per week 
 
 No vigorous job-related physical activity Skip to question 4 
 
3. How much time did you usually spend on one of those days doing vigorous 
physical activities as part of your work? 
 
_____ hours per day  _____ minutes per day 
 
4. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate physical activities like carrying light loads as part of your work?  
 Please do not include walking. 
_____ days per week 
 
 No moderate job-related physical activity Skip to question 6 
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5. How much time did you usually spend on one of those days doing moderate 
physical activities as part of your work? 
 
_____ hours per day _____ minutes per day 
 
6. During the last 7 days, on how many days did you walk for at least 10 minutes at 
a time as part of your work? Please do not count any walking you did to travel 
to or from work. 
 
_____ days per week 
 
 No job-related walking Skip to PART 2: TRANSPORTATION 
 
7. How much time did you usually spend on one of those days walking as part of 
your work? 
 
_____ hours per day _____ minutes per day 
 
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
 
These questions are about how you traveled from place to place, including to places like 
work, stores, movies, and so on. 
 
8. During the last 7 days, on how many days did you travel in a motor vehicle like 
a train, bus, car, or tram? 
 
_____ days per week 
 
 No traveling in a motor vehicle Skip to question 10 
 
9. How much time did you usually spend on one of those days traveling in a train, 
bus, car, tram, or other kind of motor vehicle? 
 
_____ hours per day _____ minutes per day 
 
Now think only about the bicycling and walking you might have done to travel to and 
from work, to do errands, or to go from place to place. 
 
10. During the last 7 days, on how many days did you bicycle for at least 10 
minutes at a time to go from place to place? 
 
_____ days per week 
 
 No bicycling from place to place Skip to question 12 
 
 
11. How much time did you usually spend on one of those days to bicycle from place 
to place? 
 
_____ hours per day _____ minutes per day 
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12. During the last 7 days, on how many days did you walk for at least 10 minutes at 
a time to go from place to place? 
 
_____ days per week 
 
 No walking from place to place Skip to PART 3: 
HOUSEWORK, HOUSE 
MAINTENANCE, AND 
CARING FOR FAMILY 
 
13. How much time did you usually spend on one of those days walking from place 
to place? 
 
_____ hours per day _____ minutes per day 
 
 
PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
This section is about some of the physical activities you might have done in the last 7 
days in and around your home, like housework, gardening, yard work, general 
maintenance work, and caring for your family. 
 
14. Think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, chopping wood, shoveling snow, or digging in the 
garden or yard? 
 
_____ days per week 
 
 No vigorous activity in garden or yard Skip to question 16 
 
 
15. How much time did you usually spend on one of those days doing vigorous 
physical activities in the garden or yard? 
 
_____ hours per day _____ minutes per day 
 
16. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate activities like carrying light loads, sweeping, washing windows, and 
raking in the garden or yard? 
 
_____ days per week 
 
 No moderate activity in garden or yard Skip to question 18 
 
17. How much time did you usually spend on one of those days doing moderate 
physical activities in the garden or yard? 
 
_____ hours per day _____ minutes per day 
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18. Once again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate activities like carrying light loads, washing windows, scrubbing floors 
and sweeping inside your home? 
 
_____ days per week 
 
 No moderate activity inside home Skip to PART 4: 
RECREATION, SPORT 
AND LEISURE-TIME 
PHYSICAL ACTIVITY 
 
19. How much time did you usually spend on one of those days doing moderate 
physical activities inside your home? 
 
_____ hours per day _____ minutes per day 
 
 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you did in the last 7 days solely for 
recreation, sport, exercise or leisure. Please do not include any activities you have 
already mentioned. 
 
20. Not counting any walking you have already mentioned, during the last 7 days, on 
how many days did you walk for at least 10 minutes at a time in your leisure 
time? 
 
_____ days per week 
 
 No walking in leisure time Skip to question 22 
 
21. How much time did you usually spend on one of those days walking in your 
leisure time? 
 
_____ hours per day _____ minutes per day 
 
22. Think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do vigorous physical 
activities like aerobics, running, fast bicycling, or fast swimming in your leisure 
time? 
 
_____ days per week 
 
 No vigorous activity in leisure time Skip to question 24 
 
23. How much time did you usually spend on one of those days doing vigorous 
physical activities in your leisure time? 
 
_____ hours per day _____ minutes per day 
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24. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate physical activities like bicycling at a regular pace, swimming at a 
regular pace, and doubles tennis in your leisure time? 
 
_____ days per week 
 
 No moderate activity in leisure time Skip to PART 5: TIME 
SPENT SITTING 
 
25. How much time did you usually spend on one of those days doing moderate 
physical activities in your leisure time? 
 
_____ hours per day _____ minutes per day 
 
 
PART 5: TIME SPENT SITTING 
 
The last questions are about the time you spend sitting while at work, at home, while 
doing course work and during leisure time. This may include time spent sitting at a desk, 
visiting friends, reading or sitting or lying down to watch television. Do not include any 
time spent sitting in a motor vehicle that you have already told me about. 
 
26. During the last 7 days, how much time did you usually spend sitting on a 
weekday? 
 
_____ hours per day _____ minutes per day 
 
 
27. During the last 7 days, how much time did you usually spend sitting on a 
weekend day? 
 
_____ hours per day _____ minutes per day 
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Fagerström Test for Cigarette Dependence 
 
 
 
Please answer the following:                  Your 
Answer: 
  
(F1) How many cigarettes per day do you 
usually smoke? (write the number on the line 
and circle the number [between 0 and 3] that 
best represents your cigarette consumption) 
 
 CIG/DAY: 
 
 10 or less 
 
11 to 20 
 
21 to 30 
 
31 or more 
0 
 
1 
 
2 
 
3 
 
(F2) How soon after you wake up do you smoke 
your first cigarette?  (circle one response) 
Within 5 minutes 
 
6-30 minutes 
 
31 or more 
 
3 
 
2 
 
0 
(F3) Do you find it difficult to refrain from 
smoking in places where it is forbidden (e.g. in 
church, at the library, in the cinema?) (circle one 
response) 
No 
 
Yes 
 
0 
 
1 
(F4) Which cigarette would you most hate to 
give up? (circle one response) 
The first of the 
morning 
 
Other 
 
1 
 
 
0 
(F5) Do you smoke more frequently in the first 
hours after waking than during the rest of the day 
(circle one) 
No 
 
Yes 
 
0 
 
1 
(F6) Do you smoke if you are so ill that you are 
in bed most of the day? (circle one response) 
No 
 
Yes 
0 
 
1 
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Physical Activity Readiness Questionnaire 
 	  
1. Has your doctor ever said that you have a heart condition and that you should only do 
physical activity recommended by a doctor? 
a. [ ] Yes 
b. [ ] No 
 
2. Do you feel pain in your chest when you do physical activity? 
a. [ ] Yes 
b. [ ] No 
 
3. In the past month, have you had chest pain when you were not doing physical 
activity? 
a. [ ] Yes 
b. [ ] No 
 
4. Do you lose your balance because of dizziness or do you ever lose consciousness? 
a. [   ] Yes 
b. [ ] No 
 
5. Do you have a bone or joint problem that could be made worse by a change in your 
physical activity? 
a. [ ] Yes 
b. [ ] No 
 
6. Is your doctor currently prescribing drugs (for example, water pills) for your blood 
pressure or heart? 
a. [ ] Yes 
b. [ ] No 
 
7. Do you know of any other reason why you should not do physical activity? 
a. [ ] Yes 
b. [ ] No 
 
 
___________________________________  
Date 
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